CURRICULUM VITAE
Michael James Burke MD
Michael James Burke MD
Professor
Department of Pediatrics
Division of Hematology and Oncology - Pediatrics
Leukemia & Lymphoma Program Director
Developmental Therapeutics Program Co-Director
Director of Translational & Clinical Research
Department of Pediatrics
Division of Hematology and Oncology - Pediatrics
Leukemia & Lymphoma Program Director
Developmental Therapeutics Program Co-Director
Director of Translational & Clinical Research
OFFICE ADDRESS: |
MACC Fund Research Center |
8701 Watertown Plank Rd |
Milwaukee, WI 53226 |
EDUCATION: |
09/1989 - 12/1993 B.S., Biological Sciences, University of California at Irvine, Irvine, CA |
01/1996 - 02/2000 M.D., Ross University School of Medicine, Portsmouth, Dominica |
09/2005 - 05/2009 Biomedical Sciences, Grand Valley State University, Allendale, MI |
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: |
07/2000 - 06/2001 Intern, Pediatrics, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA |
07/2001 - 06/2003 Resident, Pediatrics, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA |
07/2003 - 06/2006 Fellow, Pediatrics, Hematology/Oncology, Northwestern University Feingold School of Medicine, Children's Memorial Hospital, Chicago, IL |
FACULTY APPOINTMENTS: |
07/2006 - 05/2013 Assistant Professor of Pediatrics, Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Minnesota, Minneapolis, MN |
05/2013 - 07/2013 Associate Professor of Pediatrics, Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Minnesota, Minneapolis, MN |
08/2013 - 06/2020 Associate Professor of Pediatrics, Department of Pediatrics, Division of Pediatric Hematology/Oncology, The Medical College of Wisconsin, Milwaukee, WI |
2013 - Present Attending Physician, Pediatrics, Hematology/Oncology/Transplant, Children's Hospital of Wisconsin, Milwaukee, WI |
2015 - Present Attending Physician, Pediatrics, Hematology/Oncology, Froedtert Memorial Lutheran Hospital, Milwaukee, WI |
07/2020 - Present Professor of Pediatrics, Pediatrics, Pediatric Hematology/Oncology, The Medical College of Wisconsin-Children’s Hospital of Wisconsin, Milwaukee, WI |
EDUCATIONAL ADMINISTRATIVE APPOINTMENTS: |
2007 - 2012 Fellowship Director, Pediatric Hematology/Oncology and Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN |
HOSPITAL STAFF PRIVILEGES: |
2006 - 2013 Attending Physician, Pediatric Hematology/Oncology, Hennepin County Medical Center (HCMC), Minneapolis, MN |
2006 - 2013 Attending Physician, Pediatric Hematology/Oncology, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN |
2013 - Present Attending Physician, Pediatric Hematology/Oncology, Children's Hospital of Wisconsin, Milwaukee, WI |
SPECIALTY BOARDS AND CERTIFICATION: |
Board Certified | Issue Date | Expiration |
Pediatrics | 2003 | 2023 |
ABP - Hematology/Oncology | 2006 | 2026 |
Certificates | Issued By | Issue Date | Expiration |
Neonatal Resuscitation | 2000 | 2007 | |
ECFMG | 2000 | None | |
Pediatric Adv. Life Support | 2000 | 2008 | |
Licensure | Number | Issue Date | Expiration |
Illinois License | 06/24/2003 | 07/31/2008 | |
Minnesota License | 48856 | 09/09/2006 | 05/31/2014 |
Wisconsin License | 60869-20 | 05/31/2013 | 10/31/2021 |
AWARDS AND HONORS: |
1989 - 1993 Zabish Memorial Scholarship Recipient, Undergraduate Academic Scholarship. |
1991 National Champion - Men's Light Weight Double Scull, American Rowing Championships, Camden, NJ |
2000 Magna Cum Iaude, Ross University School of Medicine |
2009 - Present Best Doctors in America |
2010 - Present Cambridge Who's Who |
06/18/2015 Inducted into The Ring of Honor, Mater Dei High School |
2015 - Present Milwaukee Magazine Top Doctors - Pediatric Hematology/Oncology |
MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: |
2000 - Present American Academy of Pediatrics |
2004 - 2020 American Society of Pediatric Hematology and Oncology |
2004 - 2020 American Society of Hematology |
2006 - Present Children's Oncology Group (Full member) |
2007 - Present Pediatric Bone Marrow Transplant Consortium (PBMTC) |
2007 - 2012 American Academy of Pediatrics: Section on Young Physicians |
2007 - Present Center for International Blood & Marrow Transplant (CIBMTR) |
EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS: |
Journal Review |
New England Journal of Medicine (2) |
Leukemia Research Reports (1) |
Clinical Advances in Hematology & Oncology (1) |
Clinical Pharmacology (a) |
Journal of Clinical Medicine |
Annals of Transplantation (1) |
Biology of Blood and Marrow Transplantation (4) |
International Journal of Nanomedicine (1) |
Leukemia & Lymphoma (1) |
Pediatric Blood and Cancer (19) |
Advances and Applications |
Leukemia (1) |
Frontiers in Oncology (1) |
Blood (1) |
Bone Marrow Transplantation (2) |
Current Cancer Drug Targets (1) |
Journal of Pediatric Hematology and Oncology (4) |
British Journal of Cancer (1) |
LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
2006 - 2007 Member, Pediatric Residency Selection Committee, University of Minnesota |
2006 - 2013 Co-Chair, Pediatric Leukemia Program, University of Minnesota |
2006 - 2013 Member, Hematology/Oncology Fellowship Committee, University of Minnesota Pediatric |
2007 - 2012 Chair, Pediatric Hematology/Oncology Fellowship Committee, University of Minnesota |
2007 - 2012 Member, Pediatric Fellowship Committee, University of Minnesota |
2007 - 2009 Member, Cancer Protocol Review Committee (CPRC) - Non Therapeutic Intervention (NTI) Committee, University of Minnesota |
2008 - 2010 Member, Pediatric Resuscitation Committee, University of Minnesota |
2009 - 2013 Co-Chair, Masonic Cancer Center ALL Committee, University of Minnesota |
2009 - 2013 Member, Masonic Cancer Center, University of Minnesota |
2012 - 2013 Member, Pediatric Hematology/Oncology Faculty Position Search Committee, University of Minnesota |
2013 - Present Director, Pediatric Leukemia and Lymphoma Program, Medical College of Wisconsin/Children's Hospital of Wisconsin |
2013 - 2017 Committee Member, Pediatric Developmental Therapeutics Program, Medical College of Wisconsin - Children's Hospital of Wisconsin |
2013 - 2018 Committee Member, Pediatric Hematology/Oncology fellowship Committee, Medeical College of Wisconsin |
2014 - Present Member, Pediatric Intern Selection Committee, Children's Hospital of Wisconsin |
2014 - Present Committee Member, Clinical Research Seed Grant Review Committee, Medical College of Wisconsin Cancer Center |
2017 - 2020 Member, Cancer Center Pilot Grant Review Committee, Medical College of Wisconsin |
2017 - Present Program Co-Director, Pediatric Developmental Therapeutics Program, Medical College of Wisconsin/Children's Hospital of Wisconsin |
2017 Grant Reviewer Committee Member, Advancing a Healthier Wisconsin Endowment Research and Education Program, Medical College of Wisconsin |
2018 - Present Director, Director of Clinical and Translational Research, Children's Hospital of Wisconsin - Division of Hematology/Oncology/Bone and Marrow Transplantation |
2021 Committee Member, Promotion and Rank Committee: Development of Clinical Investigator Track, Medical College of Wisconsin |
2022 - Present Committee Member, Institutional Review Board (IRB), Medical College of Wisconsin |
2023 - Present Member, Pediatric Leukemia and Lymphoma Steering Committee, National Cancer Institute |
NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
2006 - 2007 Committee Member, Very High Risk ALL, Children's Oncology Group |
2007 - 2013 Committee Member, Pediatric Cancer Working Group, Center for International Blood anqd Marrow Transplant Research (CIBMTR) |
2007 - 2013 Committee Member, ALL Working Group, Center for International Blood and Marrow Transplant Research (CIBMTR) |
2007 - Present Committee Member, High Risk ALL, Children's Oncology Group |
2007 - 2013 Committee Member and ALL Liaison, Young Investigators Committee, Children's Oncology Group |
2008 - 2013 Committee Member, UMN Institutional PI, Treatment Advances in Childhood Leukemia & Lymphoma (TACL) |
2008 - 2012 Committee Member, Oncology Strategy Group, Pediatric Bone Marrow Transplant Consortium (PBMTC) |
2009 - 2011 Committee Member, AALL08P1:Intensified PEG-Asparaginase in High-Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study, COG - Committee, Children's Oncology Group |
2009 - Present Study Chair, TACL T2009-003, A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL |
2009 - 2011 Committee Member, ADVL0413 A Phase I Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children with Refractory Solid Tumors or Refractory Leukemias, Childrens Oncology Group |
2010 - 2012 Committee Member, ALL Relapse Task Force, Childrens Oncology Group |
2010 - 2013 Study Chair, ADVL0911 Phase I Dose-Escalation Study of Seneca Valley Virus (SVV-011), Childrens Oncology Group |
2011 - 2019 Study co-chair, AALL1131 A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND#73789) NSC#606869) in the Very High Risk Stratum, Childrens Oncology Group |
2012 - Present Member, TACL Steering Committee, Medical College of Wisconsin |
2012 - 2022 Member, TACL Steering & Prioritization Committee, Medical College of Wisconsin |
2013 - Present Member/PI, TACL MCW Institutional PI, Medical College of Wisconsin |
2013 - Present Member, Acute Lymphoblastic Leukemia, Advisory Board, Onyx Pharmaceuticals |
2013 - Present Member, Acute Lymphoblastic Leukemia, Advisory Board, Seattle Genetics Inc. |
2013 - Present Member, Acute Lymphoblastic Leukemia, Advisory Board, Jazz Pharmaceutical |
2015 - 2021 Study Chair, Phase Ib Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia, TACL/AMGEN |
2015 - Present Abstract Reviewer, Acute Lymphoblastic Leukemia (ALL) Clinical Studies, American Society of Hematology (ASH) Meeting |
2015 - Present Committee Member, Acute Lymphoblastic Leukemia (ALL) Clinical Studies, American Society of Hematology (ASH) Meeting Abstract Reviewer |
2015 - Present Committee Member, Chronic Myeloid Leukemia (CML) Working Group, Children's Oncology Group (COG) |
2016 - Present Ad-Hoc Consultant for Oncologic Drug Advisory Committee (ODAC), U.S. Food and Drug Administration (FDA) |
2018 - 2022 Scientific Chair, TACL Steering & Prioritization Committee |
2019 - Present Committee Chair, CCTL019G220IJ/CASSIOPEIA Novartis/Children’s Oncology Group: A Phase II trial of Tisagenlecleucel first-line High-Risk pediatric and young adult patients with B-ALL who are minimal residual disease positive at the end of consolidation therapy (AALL1721): Data Safety Monitoring Committee |
2022 - Present Associate Editor, Journal of Adolescent and Young Adult Oncology, Frontiers in Adolescent Medicine |
2023 - Present Member, Pediatric Leukemia and Lymphoma Steering Committee, National Cancer Institute |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INVITED LECTURES/WORKSHOPS/PRESENTATIONS: |
Local |
Burke M, "Emergency Department Presentations of Oncologic Diagnoses.", Hennepin County Medical Center, Minneapolis, Minnesota, 09/04/2006 |
Burke M, "Evaluation of Anemia in the Outpatient Setting.", Buffalo, Minnesota, 03/12/2007 |
Burke M, "Past, Present and Future of Childhood Leukemia.", Pediatric Grand Rounds, University of Minnesota, Minneapolis, Minnesota, 08/29/2007 |
Burke M, "Acute Lymphoblastic Leukemia.", University of Minnesota 10th Annual Nursing Conference, Minneapolis, Minnesota, 11/08/2007 |
Burke M, "Lead Induced Anemia.", Family Medicine Update 2008, Minneapolis, Minnesota, 05/13/2008 |
Burke M, "Guidelines for Post-Hematopoietic Cell Transplant (HCT) Dasatinib in Ph+ Leukemia.", University of Minnesota BMT Conference, Minneapolis, Minnesota, 06/02/2008 |
Burke M, "Pediatric & Childhood Lymphomas.", 5th Annual Minnesota Lymphoma Workshop, Lymphoma Research Foundation, Minnesota, 10/18/2008 |
Burke M, "Wilm's Tumor.", 11th Annual Nursing Conference, University of Minnesota, Minneapolis, Minnesota, 11/06/2008 |
Burke M, "When the Tide Turns in Pediatric Leukemia, 12th Annual Nursing Conference, University of Minnesota, Minneapolis, Minnesota, 11/12/2009 |
Burke M, "Salvaging the Relapsed Leukemia Patient.", University of Minnesota Pediatric Intensive Care Conference, University of Minnesota, Minneapolis, Minnesota, 03/29/2010 |
Burke M, "Anemia in Today's FP Clinic Setting." Annual Family Medicine Update, Topics & Advances in Pediatrics, Minneapolis, Minnesota, 06/10/2010 |
Burke M, "Anemia with a Vegetarian Diet.", University of Minnesota Topics and Advances in Pediatrics, Minneapolis, Minnesota, 06/10/2010 |
Burke M, "When the Tide Turns in Pediatric Leukemia.", 13th Annual Nursing Conference, University of Minnesota, Minneapolis, Minnesota, 11/13/2010 |
Burke M, "Epigenetics in Leukemia - Changing the Relapse Signature.", Children's Hospital Pediatric Research Seminar, University of Minnesota Amplatz, Minneapolis, Minnesota, 11/14/2011 |
Burke M, "Genetic Mutations in Childhood ALL - How they change the game.", 14th Annual Nursing Conference, University of Minnesota, Minneapolis, Minnesota, 01/26/2012 |
Burke M, "Lower cyclosporine A (CSA) exposure after umbilical cord blood transplantation in acute leukemia is associated with lower survival but not relapse.", University of Minnesota BMT Conference, Minneapolis, Minnesota, 05/14/2012 |
Burke M, How to Recognize Leukemia and New Advances in Treatment.", Topics & Advances in Pediatrics, Minneapolis, Minnesota, 06/07/2012 - 06/08/2012 |
Burke M, "Can we manipulate gene expression to control leukemia?" University of Minnesota and People's Republic of China: Health Connections Symposium., University of Minnesota BMT Conference, Minneapolis, Minnesota, 10/08/2012 |
Burke M, "Meaning and clinical implication of MRD and remission status in adult and pediatric acute leukemia." University of Minnesota BMT Conference, University of Minnesota BMT Conference, Minneapolis, Minnesota, 11/19/2012 |
Burke M, "COG AALL1131 High Risk and Very High Risk B-ALL.", 15th Annual Nursing Conference, Minneapolis, Minnesota, 01/17/2013 |
Burke M, Raising the Awareness of AYA Leukemia Outcomes, First Annual Adolescent and Young Adult Cancer Symposium, Milwaukee, WI, 10/23/2013 |
Burke M, Raising the Awareness of AYA Leukemia Outcomes, Third Annual Controversies in Hematologic Malignancies Symposium, Milwaukee, WI, 03/08/2014 |
Burke M, Epigenetics in Acute Leukemia, Hematologic Malignany and Transplantation Conference, Medical College of Wisconsin, 04/24/2014 |
Burke M, Childhood Leukemia, HOT Nursing Education Day, Children's Hospital of Wisconsin, 11/12/2014 |
Burke M, Reversing Chemoresistance in Acute Leukemia, Children’s Research Institute Seminar Series, Children’s Hospital of Wisconsin, Milwaukee, WI, 09/14/2018 |
Burke M, Understanding the Leukemia Niche in Acute Myeloid Leukemia, Targeting with IL-12, Northwestern Mutual Cancer Symposium, Miller Park, Milwaukee, WI, 05/09/2019 |
M Burke, "Emerging Therapies and Survivorship in Pediatric ALL; Treatment of ALL in Children – Where We Have Been and Where Are We Going.", Leukemia & Lymphoma Society, Virtual Program, 09/15/2020 |
M, Burke, Epigenetic Reprogramming in Pediatric AML, Cancer Center Seminar Series: Discovery & Developmental Therapeutics Program, Medical College of Wisconsin, 11/20/2020 |
Burke M, Epigenetic Reprogramming in Pediatric AML, Cancer Center Seminar Series: Discovery & Developmental Therapeutics Program, Medical College of Wisconsin, 11/20/2020 |
M, Burke, Introduction to Pediatric Leukemias, Medical Student Year 2 Heme-Lymph Lecture, Medical College of Wisconsin, 11/23/2020 |
M, Burke, Epigenetic Reprogramming in Pediatric AML., Integrative Science Meeting, Medical College of Wisconsin, 02/14/2023 |
Burke, M, Childhood Leukemia, Resident Noon Lecture, 04/11/2023 |
Burke, M., Designing Clinical Trials, Student Centered Pipeline to Advance Research in Cancer Careers (SPARCC) lecture, Milwaukee, WI, 07/17/2023 |
National |
Burke M, "A phase II study of recombinant immunotoxin HA22 in children with relapsed ALL and MRD positivity prior to allo-HCT.", Oncology Strategy Session, Annual PBMTC Meeting 2009, Dallas, TX., 2009 |
Burke M, "The use of the tyrosine kinase inhibitor (TKI) imatinib as post-allo-HCT prophylaxis in children with Ph+ ALL.", Oncology Strategy Session of Annual PBMTC Meeting, Dallas, TX, 2009 |
Burke M, "Changing the Approach to Relapse Leukemia--Epigenetic Alterations.", Northwestern University Children's Memorial Hospital, Chicago, Illinois, 07/09/2010 |
Burke M, "Oncolytic Virus Trial.", Children's Neuroblastoma Cancer Foundation, Chicago, Illinois, 07/10/2010 |
Burke M, "Treatment of newly diagnosed high risk B-precursor ALL - AALL1131.", Children's Oncology Group Fall Meeting Acute Lymphoblastic Leukemia (ALL) General Session, Dallas, Texas, 09/2010 |
Burke M, "A phase 1 dose escalation study of Seneca Valley Virus (NTX-010), a replication-competent picornavirus, in relapsed/refractory pediatric patients with neuroblastoma, rhabdomyosarcoma, or rare tumors with neuroendocrines features - ADVL0911.", Children's Oncology Group Fall Meeting Developmental Therapeutics (DVL) General Session, Dallas, Texas, 09/2010 |
Burke M, "Addressing the Challenges of Relapse Leukemia.", Pediatric Grand Rounds - Blank Children's Hospital, Des Moines, Iowa, 04/22/2011 |
Burke M, "A phase III randomized trial for newly diagnosed high risk B-precursor acute lymphoblastic leukemia (ALL) testing clofarabine (IND#73789, NSC#606869) in the very high risk stratum - AALL1131.", Children's Oncology Group Fall Meeting, Acute Lymphoblastic Leukemia (ALL) General Session, Atlanta, Georgia, 09/2011 |
Burke M, "A phase 1 dose escalation study of Seneca Valley Virus (NTX-010), a replication-competent picornavirus, in relapsed/refractory pediatric patients with neuroblastoma, rhabdomyosarcoma, or rare tumors with neuroendocrine features - ADVL0911.", Children's Oncology Group Fall Meeting, Developmental Therapeutics (DVL) General Session, Atlanta, Georgia, 09/2011 |
Burke M, "A phase III randomized trial for newly diagnosed high risk B-precursor acute lymphoblastic leukemia (ALL) testing clofarabine (IND#73789, NSC#606869) in the very high risk stratum - AALL1131.", Children's Oncology Group Fall Meeting, Clinical Research Associate (CRA) General Session, Atlanta, Georgia, 09/2011 |
Burke M, "A Phase I Dose Escalation Study of Seneca Valley Virus (NTX-010), a Replication-Competent Picornovirus, in Relapsed/Refractory Pediatric Patients with Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors with Neuroendocrine Features.", CTEP Early Drug Development Meeting, Bethesda, Maryland, 10/03/2011 |
Burke M, "Clinical Development of Epigenetic Therapy in Childhood ALL: Reprogramming ALL Blasts to Reverse Chemoresistance.", ASPHO Meeting, New Orleans, Louisiana, 05/11/2012 |
Burke M, "Minimal Residual Disease Case Studies", Medical Science Liaison Education Summit, Jazz Pharmaceuticals, Philadelphia, PA, 07/16/2012 - 07/19/2012 |
Burke M, "A phase 1 dose escalation study of Seneca Valley Virus (NTX-010), a replication-competent picornavirus, in relapsed/refractory pediatric patients with neuroblastoma, rhabdomyosarcoma, or rare tumors with neuroendocrine features - ADVL0911.", Children's Oncology Group Fall Meeting, Developmental Therapeutics (DVL) General Session, Atlanta, Georgia, 09/2012 |
Burke M, "A phase III randomized trial for newly diagnosed high risk B-precursor acute lymphoblastic leukemia (ALL) testing clofarabine (IND#73789, NSC#606869) in the very high risk stratum - AALL1131.", Children's Oncology Group Fall Meeting, Acute Lymphoblastic Leukemia (ALL) General Session, Atlanta, Georgia, 09/2012 |
Burke M, "Clinical development of epigenetic therapy in childhood ALL: reprogramming ALL blasts to reverse chemotherapy resistance.", Pediatric Tumor Board - Nationwide Children's Hospital, Columbus, Ohio, 10/26/2012 |
Burke M, "Clinical development of epigenetic therapy in childhood ALL: reprogramming ALL blasts to reverse chemotherapy resistance.", Pediatric Tumor Board, Children's Hospital of Wisconsin, Milwaukee, WI, 11/08/2012 |
Burke M, "A phase III randomized trial for newly diagnosed high risk B-precursor acute lymphoblastic leukemia (ALL) testing clofarabine (IND#73789, NSC#606869) in the very high risk stratum - AALL1131.", Acute Lymphoblastic Leukemia (ALL) General Session, Children's Oncology Group Spring Meeting, Minnesota, 04/10/2013 |
Burke M, "Childhood Cancers: To Transplant or Not to Transplant - Pediatric Philadelphia-positive (Ph+) Acute Lymphoblastic Leukemia.", ASCO Annual Meeting, Chicago, IL, 06/02/2013 |
Burke M, "High-Risk and Very High-Risk ALL", Jazz Pharmaceuticals Symposium: Oncology University - All About Acute Lymphoblastic Leukemia, Chicago, IL, 08/01/2013 |
Burke M, “Understanding the Landscape of Relapsed ALL”, ALL Advisory Board Meeting, Onyx Pharmaceuticals, San Francisco, CA, 09/27/2013 |
Burke M, A phase III randomized trial for newly diagnosed high risk B-precursor acute lymphoblastic leukemia (ALL) testing clofarabine (IND#73789, NSC#606869) in the very high risk stratum - AALL1131.", Acute Lymphoblastic Leukemia (ALL) General Session, Children's Oncology Group Fall Meeting, Dallas, TX, 10/09/2013 |
Burke M, “Allogeneic hematopoietic cell transplantation outcomes for pediatric T-ALL: New and Old.”, Stem Cell Transplant in ALL Session, Children’s Oncology Group Fall Meeting, Dallas, TX, 10/10/2013 |
Burke M, “The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia.”, Chicago, IL, 02/15/2014 |
Burke M, “The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia.”, Chicago, IL, 02/18/2014 |
Burke M, “The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia.”, Chicago, IL, 02/25/2014 |
Burke M, “The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia.”, Fargo, ND, 04/22/2014 |
Burke M, “Protein-Based Therapeutic Immunogenicity: Clinical Implications.”, Pittsburgh, PA, 04/30/2014 |
Burke M, “Protein-Based Therapeutic Immunogenicity: Clinical Implications.”, Charlottwsville, VA, 05/13/2014 |
Burke M, “Protein-Based Therapeutic Immunogenicity: Clinical Implications.”, Broadview Heights, OH, 05/20/2014 |
Burke M, The Role of Erwinaze (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia., Charlottesville, VA, 07/15/2014 |
Burke M, The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia., Peoria, IL, 07/30/2014 |
Burke M, The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia., Phoenix, AZ, 09/08/2014 |
Burke M, The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia., Santa Barbara, CA, 09/09/2014 |
Burke M, The Role of Erwinaze (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia, Charleston, SC, 10/13/2014 - 10/14/2014 |
Burke M, Understanding the Landscape to Relapse ALL, Philadelphia, PA, 10/21/2014 |
Burke M, "Changing the Approach to Relapse ALL – one methylated histone at a time”, Research Seminar, University of Texas MD Anderson Cancer Center, Houston, TX, 01/13/2015 |
Burke M, “Erwinase – asparaginase Erwinia chrysanthemi”, Live National Broadcast, New York, NY, 01/15/2015 |
Burke M, “The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia.”, Webinar, 02/10/2015 |
Burke M, “Feasibility of intensive post-Induction therapy incorporating clofarabine (CLOF) n the very high risk (VHR) stratum of patients with newly diagnosed high risk B lymphoblastic leukemia (HR B-ALL): Children’s Oncology Group AALL1131”, ASCO Annual Meeting Oral Presentation, Chicago, IL, 05/2015 |
Burke M, Feasibility of intensive post-Induction therapy incorporating clofarabine (CLOF) in the very high risk (VHR) stratum of patients with newly diagnosed high risk B lymphoblastic leukemia (HR B-ALL): Children’s Oncology Group AALL1131, ASCO Annual Meeting - Oral Presentation, Chicago, IL, 05/2015 |
Burke M, Changing the Approach to Relapse ALL – one methylated histone at a time, Pediatric Grand Rounds, Doernbecher Children's Hospital, Portland, OR, 09/2015 |
Burke M, Changing the Approach to Relapse ALL - one Methylated histone at a time, Pediatric Grand Rounds, Doernbecher Children's Hospital, Portland, OR, 11/2015 |
Burke M, Acute Lumphoblastic Leukemia Clinical Studies 1, American Society of Hematology (ASH) Annual Meeting, Orlando, FL, 2015 |
Burke M, "Novel Indications/Considerations of BMT for ALL in CR1", ASPHO/PBMTC Meeting, Minneapolis, MN, 05/11/2016 |
Burke M, “New Frontiers: Advances in Stem Cell Therapy for Pediatric ALL: Session Chair and Moderator", ASPHO/PBMTC Educational Meeting, Minneapolis, MN, 05/11/2016 |
Burke M, Children's Oncology Group (COG) B-ALL Protocols, An Update, Society of Adolescent and Young Adult Oncology (SAYAO) Meeting, Newport Beach, CA, 11/14/2016 |
Burke M, What is the Role of Stem Cell Transplant in the New World of Immune-Biopharmaceuticals and CAR-T Cells?, Society of Adolescent and Young Adult Oncology (SAYAO) Meeting, Newport Beach, CA, 11/15/2016 |
Burke M, Substitution with Cyclophosphamide and Etoposide Does Not Improve Outcome for Children and Young Adults with Very High-Risk B-Lymphoblastic Leukemia: Children’s Oncology Group (COG) Study AALL1131., 49th Congress of the International Society of Paediatric Oncology (SIOP) Meeting, Washington, DC, 10/13/2017 |
Burke M, Moving to the Age of Personalized Medicine: The COG Experience, Key Note Speaker
Catalyst Symposium on Adolescent and Young Adult (AYA) Oncology, UCLA, Los Angeles, CA, 10/20/2017 |
Burke M, A Closer Look at the Treatment and Toxicity Management of ALL, University of Michigan, Ann Arbor, MI, 08/14/2018 |
Burke M, A Deeper Response: MRD-Negativity Results from a Study in Adult B-Cell Precursor Acute Lymphoblastic Leukemia., Miami, FL, 08/21/2018 |
Burke M, A Deeper Response: MRD-Negativity Results from a Study in Adult B-Cell Precursor Acute Lymphoblastic Leukemia., Los Angeles, CA, 09/05/2018 |
M, Burke, Epigenetic Reprogramming in Pediatric AML., 8th Annual Northwestern Mutual Pediatric Cancer Symposium., Hybrid Meeting held in Milwaukee, WI with national attendance., 06/01/2022 - 06/02/2022 |
International |
Burke M, "A phase 1 dose escalation study of Seneca Valley Virus (NTX-010), a replication-competent picornavirus, in relapsed/refractory pediatric patients with neuroblastoma, 7th International Meeting on Replicating Oncolytic Virus Therapeutics, Quebec, Canada, 06/13/2013 |
Burke M, Novel epigenetic strategies in North America, New Agents in Leukemia Meeting, Amsterdam, Netherlands, 10/05/2016 |
MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED: |
Medical Students |
Danielle Olson, Medical College of Wisconsin, 2017 - 2018 Outpatient Clinical Preceptor, MACC Fund Oncology Clinic, Children’s Hospital of Wisconsin; Outpatient clinical preceptor during years 1 and 2 of medical school |
Hannah Lohmeier, Medical College of Wisconsin, 2017 - 2018 Outpatient clinical preceptor, MACC Fund Oncology Clinic, Children’s Hospital of Wisconsin; Outpatient clinical preceptor during years 1 and 2 of medical school. |
Clinical/Research Fellows |
Nathan Schloemer, MD, Medical College of Wisconsin, 2013 - 2015 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Schloemer with a clinical research project that resulted in a manuscript as 1st author. (PMID 28452856) |
Melissa Acquazzino, MD, Medical College of Wisconsin, 2014 - 2016 “A randomized controlled trial investigating topical caphasol for prevention of mucositis in children, adolescent and young adults receiving chemotherapy or head and neck radiation.” Medical College of Wisconsin; Project Mentor |
Neel Bhatt, MD, Medical College of Wisconsin, 2016 - 2018 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Bhatt with an invited review article that resulted in a manuscript as 1st author. (Bhatt BS, Phelan R, Burke MJ. The Role of Hematopoietic Stem-Cell Transplantation in First Remission in Pediatric Acute Lymphoblastic Leukemia: A Narrative Review. Journal of Pediatrics Review. 2017 July;5(2):e10831. doi:10.5812/jpr.10831) |
Larisa Broglie, MD, Medical College of Wisconsin, 2017 Fellowship Mentor, I provided mentoring with development of a manuscript that resulted in a publication with Dr. Broglie as 1st author. |
Kerri Becktell, MD, Medical College of Wisconsin, 2017 - 2019 Fellowship Mentor, I provided mentoring with development of a manuscript that resulted in a publication with Dr. Becktell as 1st author. |
Lauren Pommert, MD, Medical College of Wisconsin, 2017 - 2019 Fellowship Mentor, I provided research mentoring along with Sid Rao, MD, PhD as well as mentoring Dr. Pommert with an invited book chapter (Critical Care of the Immune Compromised Pediatric Hematology/Oncology Patient) on Acute Leukemia. This work resulted in a Dr. Pommert listed as a co-author. |
Nicole Liberio, MD, Medical College of Wisconsin, 2020 Fellowship Mentor., I provided mentoring with a manuscript with Dr. Liberio, that resulted in 2nd authorship. PMID: 32398599 |
EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED: |
High School Students |
Musaab Tareen, Pewaukee High School, 2022 - 2023 Insight Mentoring Program |
Mariavarsha Prem Rajesh, Pewaukee High School, 2023 - 2024 Insight Mentoring Program- Health Sciences, monthly meetings throughout the school year to discuss the health care career |
Medical Students |
Patrick Chisum, First Year Medical Student, Medical College of Wisconsin, MACC Fund Oncology Clinic, Children’s Hospital of Wisconsin, 2013 - 2014 Outpatient Clinical Preceptor, MACC Fund Oncology Clinic, Children’s Hospital of Wisconsin; Outpatient clinical preceptor during years 1 and 2 of medical school |
Tyler Lennon, First Year Medical Student, Medical College of Wisconsin, MACC Fund Oncology Clinic, Children’s Hospital of Wisconsin, 2014 - 2015 Outpatient Clinical Preceptor, MACC Fund Oncology Clinic, Children’s Hospital of Wisconsin; Outpatient clinical preceptor during years 1 and 2 of medical school |
Lauren Barta, First Year Medical Student, Medical College of Wisconsin, MACC Fund Oncology Clinic, Children’s Hospital of Wisconsin, 2015 - 2016 Outpatient Clinical Preceptor, MACC Fund Oncology Clinic, Children’s Hospital of Wisconsin; Outpatient clinical preceptor during years 1 and 2 of medical school |
Peter Johnson, Medical College of Wisconsin, MACC Fund Oncology Clinic, 2019 - 2020 First Year Medical Student, Children’s Hospital of Wisconsin; Outpatient clinical preceptor during years 1 and 2 of medical school. |
Nitha Sridhar, Medical College of Wisconsin, MACC Fund Oncology Clinic, 2019 First Year Medical Student, Children’s Hospital of Wisconsin; Outpatient clinical preceptor during years 1 and 2 of medical school. |
Meghan Gallagher, Medical College of Wisconsin, MACC Fund Oncology Clinic, 2020 - 2021 First Year Medical Student, Children’s Hospital of Wisconsin; Outpatient clinical preceptor during years 1 and 2 of medical school. |
Danielle Karch, Medical College of Wisconsin, MACC Fund Oncology Clinic, 2021 - 2022 First Year Medical Student, Children’s Hospital of Wisconsin; Outpatient clinical preceptor during years 1 and 2 of medical school |
Clinical/Research Fellows |
Vivian Nnebe, MD, University of Minnesota, 2006 - 2009 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Nnebe in identifying her scholarly research fellowship project in the area of benign hematology and working on more efficient studying methods during fellowship. |
Troy Lund, MD, University of Minnesota, 2006 - 2009 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Lund in identifying his scholarly research fellowship project in the area of bone marrow transplantation and submitting and receiving a St. Baldrick’s Fellowship Research Grant. |
Heather Stefanski, MD, University of Minnesota, 2007 - 2010 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Stefanski in identifying her scholarly research fellowship project in the area of bone marrow transplantation and submitting and receiving a St. Baldrick’s Fellowship Research Grant. |
Jill Beck, MD, University of Minnesota, 2007 - 2010 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Beck in identifying her scholarly research fellowship project in the area of bone marrow transplantation and mentoring her with 2 clinical research projects which both resulted in manuscripts with Dr. Beck as 1st author (PMID: 20856210, PMID: 19908296) |
Jennifer McCormack, MD, University of Minnesota, 2008 - 2011 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. McCormack in identifying her scholarly research fellowship project in the area of acute myeloid leukemia. |
Leslie Mortland, MD, University of Minnesota, 2008 - 2011 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Mortland in identifying her scholarly research fellowship project in the area of acute myeloid leukemia. |
Andrew Dietz, MD, University of Minnesota, 2008 - 2011 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Dietz in identifying his scholarly research fellowship project in the area of survivorship and bone marrow transplantation. |
Heather Bechtel, MD, University of Minnesota, 2009 - 2012 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Bechtel in identifying her scholarly research fellowship project in the area of benign hematology as well as working on more efficient studying methods during fellowship. |
Nicole Karras, MD, University of Minnesota, 2009 - 2012 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Karras in identifying her scholarly research fellowship project in the area bone marrow transplantation. |
Christina Ross, MD, University of Minnesota, 2010 - 2011 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Ross in identifying her scholarly research fellowship project in the area of leukemia cytogenetics. |
Lucie Turcotte, MD, University of Minnesota, 2010 - 2012 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Turcotte in identifying her scholarly research fellowship project in the area of leukemia epidemiology. |
Maggie Skrypek, MD, University of Minnesota, 2011 - 2013 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Skrypek in identifying her scholarly research fellowship project in the area of neuro-oncology. |
Jennifer Orozco, MD, University of Minnesota, 2011 - 2013 Fellowship Mentor, I provided career mentoring as well as mentoring Dr. Orozco in identifying her scholarly research fellowship project in the area of osteosarcoma. |
Adam Lamble, MD, Oregon Health & Science University, 2016 - 2019 Career Mentor, I provided career mentoring as well as mentoring Dr. Lamble with grant and manuscript submissions and provided opportunities to review manuscript submissions as an ad hoc journal reviewer. (PMID 28686179) |
Sneha Tandon, MD, Pediatric Leukemia/Lymphoma Fellow Toronto Sick Kids, 2019 ASPHO Mentor/Mentee Program |
Residents |
Julie Bennett, MD, University of Minnesota, 2009 - 2012 |
Nathan Gossai, MD, University of Minnesota, 2011 - 2014, Mentored Dr. Gossai in 3 clinical research projects which all led to manuscripts in which he was the first author (24317126) and second author (PMID 24185590, 22960388). |
Vanessa McFadden, MD, Children's Hospital of Wisconsin, 2014 - 2016 Faculty Mentor, Pediatric Intern/Resident |
Daren Diiorio, MD, Children's Hospital of Wisconsin, 2016 - 2017 Faculty Mentor, Pediatric Intern/Resident |
Victor Redmon, MD, Children's Hospital of Wisconsin, 2017 - 2018 Faculty Mentor, Pediatric Intern/Resident |
Jared Squires, MD, Children’s Hospital of Wisconsin, 2021 - 2022 Faculty Mentor, Pediatric Intern/Resident |
Sarah Anderson, MD, Children's Hospital of Wisconsin, 2022 - 2023 Pediatric Intern/Resident |
Faculty |
Robyn Dennis, MD, Nationwide Children's Hospital - Columbus, OH, 2012 - 2015 Faculty Mentor, I provided career mentoring for Dr. Dennis. |
Sarah Lo, MD, Cornell University, NY, 2012 - 2013 Faculty Mentor, I provided career mentoring for Dr. Lo. |
Agne Taraseviciute, MD, Children's Hospital of Los Angeles, 2017 - Present Faculty Mentor, I provide career mentoring for Dr. Taraseviciute which included co-authors on a manuscript and assisting her through a job change (Seattle to Children’s Hospital of Los Angeles) |
Zach Graff, MD, Assistant Professor, Children's Wisconsin, Milwaukee, WI, 2022 - Present Faculty Mentor, I provide career mentoring for Dr. Graff in addition to disease specific mentoring regarding leukemia research and leukemia related activities |
Nathan Schloemer, MD, Assistant Professor, Children's Wisconsin, Milwaukee, WI, 2023 - Present Faculty Mentor, I provide career mentoring for Dr. Schloemer in addition to disease specific mentoring regarding sarcoma early phase clinical trial research |
AD-HOC MANUSCRIPT REVIEW: |
151 manuscript reviews
Acta Pharmacologica Sinica (1); American Journal of Hematology (3); American Journal of Transplantation (1); Annals of Hematology (1); Annals of Transplantation (1); Advances and Applications Current Cancer Drug Targets (1); Biology of Blood and Marrow Transplantation (11); Blood (3); Blood and Lymphatic Cancer (2); Blood Advances (7); Blood Reviews (3); Bone Marrow Transplantation (2); British Journal of Cancer (1); British Journal of Hematology (2); Cancer (3); Clinical Advances in Hematology & Oncology (1); Clinical Cancer Research (1); Clinical Pharmacology (1); European Journal of Pharmacology (2); Hematologica (2); Infection and Drug Research (1); International Journal of Nanomedicine (1); Frontiers in Immunology (1); Frontiers in Oncology (4); Frontiers in Pediatrics (2); Frontiers Pharmacology (1); Journal of Blood Medicine (1); Journal of Clinical Medicine (1); Journal of Clinical Oncology* (25); Journal of Pediatric Hematology and Oncology (19); Leukemia (1); Leukemia & Lymphoma (6); Leukemia Research Reports (1); Medical Epigenetics (1);Molecular Therapy (1); New England Journal of Medicine (3); Pediatric Blood and Cancer (24); Pediatric Research (3); Pediatric Transplantation (1); PLOS One (1); Therapeutic Advances in Hematology (1); Transplantation and Cellular Therapy (2); Translational Pediatrics (1). |
Frontiers in Adolescent Medicine: 3 manuscript review
Adolescent and Young Adult Oncology (3)
|
CONCORTIA AND INDUSTRY CLINICAL TRIALS: |
2010 - 2011 Children’s Oncology Group (COG) COG AALL07P4: A Pilot Study of Intravenous EZN-2285 (CS-PEG E. Coli L-Asparaginase, IND# 100594) or Intravenous Oncaspar in the Treatment of Patients with High-Risk Acute Lymphoblastic Leukemia (ALL), UMN Institutional PI |
2013 - 2015 TACL Consortium: A Phase I Dose Finding Study of Panobinostat in Children with Refractory Hematologic Malignancies, CHW Institutional PI .
|
2013 - 2015 TACL Consortium: A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL, Study Chair.
|
2013 - 2015 TACL Consortium: A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in Relapse T-ALL): A Joint Study of TACL, POETIC and ITCC.
|
2013 - 2015 Pfizer Expanded Access Myelotarg Protocol for Treatment of Patients with Relapsed/Refractory AML, CHW Institutional PI.
|
2013 - 2014 TACL Consortium: A Phase I Study of 5-Azacytidine in Combination with Chemotherapy for Children with Relapsed or Refractory ALL or AML, CHW Institutional PI.
|
2015 - Present TACL/AMGEN: A Phase Ib/II Study of Carfilzomib in Combination with UK ALLR3 Induction Backbone in Children with Relapsed or Refractory ALL, Study Co-Chair.
|
2016 - 2017 DFCI KPT-330: A Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML, CHW Institutional PI.
|
2016 - 2019 TACL Consortium: A Phase I Trial of Temsirolimus in Combination with Etoposide and clophosphamide in Children with Relapsed ALL and NHL, CHW Institutional PI.
|
2016 - 2020 DFCI-MTT: Matched Targeted Therapy Recommendation for Patients with Recurrent,Refractory or High-Risk Leukemias, CHW Institutional PI.
|
2017 - Present TACL Consortium: A Pilot Study of Vincristine Sulfate Liposome Injection in Combination with UK ALLR3 Induction Chemotherapy for Children, Adolescents and Young Adults with Relapse ALL, CHW Institutional PI. |
2017 - 2020 TACL Consortium: Epigenetic Reprogramming in Relapse AML: A phase I study of decitabine and vorinostat followed by FLAG in children and young adults in relapsed/refractory AML, Study Chair
|
CONSULTING POSITIONS: |
2009 - Present Best Doctors InterConsultation(Pediatric Hematology/Oncology) |
2014 - 2019 JAZZ Pharmaceuticals – Speaker Bureau for Pediatric Acute Lymphoblastic Leukemia
|
2017 - 2019 Shire Pharmaceuticals - Speaker Bureau and Consultant for Pediatric Acute Lymphoblastic Leukemia |
2018 - 2019 AMGEN Pharmaceuticals - Speaker Bureau and Consultant for Pediatric Acute Lymphoblastic Leukemia |
2020 - Present CASSIOPEIA Phase II Children’s Oncology Group Trial (AALL1721) Data Safety Monitoring Committee (DSMC) Chair |
DEVELOPMENT OF LOCAL RESEARCH CLINICAL TRIALS: |
2007 - 2013 Cancer Experimental Therapeutics Initiative Program (CETI): MT2008-29R A Therapeutic Trial of Decitabine and Vorinostat in Combination with Chemotherapy for Relapsed/Refractory ALL or LL, University of Minnesota, Minneapolis, MN, Study Chair.
|
2008 - 2009 University of Minnesota
Fetal Cells in the Maternal Circulation: A Childhood Leukemia Study,
Principal Investigator
|
2008 - 2013 University of Minnesota Leukemia and MDS Tissue Bank, Principal Investigator |
2009 - 2012 Cancer Experimental Therapeutics Initiative Program (CETI): MT2008-33R A Therapeutic Trial of Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory ALL, Study Chair. University of Minnesota, Minneapolis, MN. |
2013 - 2016 A Phase 2 Study Investigating Clofarabine, Cyclophosphamide and Etoposide for Children, Adolescents and Young Adults (AYA) with Acute Leukemia and Minimal Residual Disease, Study Chair. Medical College of Wisconsin/Children’s Hospital of Wisconsin, Milwaukee, WI |
2013 - Present Treatment Effects in Children and Adolescent/Young Adults with Leukemia or Lymphoma, Children’s Hospital of Wisconsin, Milwaukee, WI. Principal Investigator.
|
2014 - 2017 Epigenetic Reprogramming in Relapse AML: A Phase I Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF in Children and Young Adults with Relapsed/Refractory AML, Children’s Hospital of Wisconsin, Milwaukee, WI, Study Chair. |
2020 - 2022 Blinatumomab Bridging Therapy in High-Risk B-ALL: A Phase 2 Study. Children’s Hospital of Wisconsin, Milwaukee, WI. Principal Investigator. |
2020 - 2022 Alpha/Beta T-cell and B-cell Depleted Allogeneic Transplantation Followed by Blinatumomab Therapy for High-Risk BALL: A Pilot Study. Children’s Hospital of Wisconsin, Milwaukee, WI. Study Co-Chair. |
2023 - Present A Phase I Study of Venetoclax to Augment Epigenetic Modification and Chemotherapy in Pediatric and Young Adult Patients with Relapsed and Refractory Acute Myeloid Leukemia. A Pilot Study. Children’s Wisconsin, Milwaukee, WI. Study Co-Principal Investigator. |
2023 - Present Children’s Oncology Group (COG) COG ACCL1931: Randomized Trial of Levocarnitine
Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults
Newly Diagnosed with Acute Lymphoblastic Leukemia. Study Vice-Chair |
INVITED GRANT REVIEWER: |
2015 - 2018 Rally Foundation |
2016 - 2018 St. Baldrick's Foundation |
2016 - 2022 Alex's Lemonade Stand Foundation for Childhood Cancer |
2017 - 2018 Vince Lombardi Cancer Foundation |
2018 Pediatric Cancer Research Fund (PCRF) |
INVITED MANUSCRIPT EDITORIAL ARTICLES (PEER REVIEWED): |
01/2016 Burke MJ. Minimal residual disease in NPM1-mutated AML. New England Journal of Medicine 2016 January 20. PubMed PMID:26789634 |
07/2018 Burke MJ. The addition of IKZF1 deletion in risk stratification for children with newly diagnosed B-acute lymphoblastic leukemia leads to improved survival: Results of the Malaysia-Singapore ALL 2010 study. Journal of Clinical Oncology July 2018. Audio PodCast: https://urldefense.proofpoint.com/v2/url?u=http-3A__ascopubs.org_journal_jco&d=DwIGaQ&c=aFamLAsxMIDYjNglYHTMV0iqFn3z4pVFYPQkjgspw4Y&r=K4fL9T8q6SIoC7T_CXzgSQ&m=yZTM8eU4CVXdm2zbe8BK0AJhrhSzcRtZ29_-8ixm2iU&s=DQV8fI1-0UE32wdFt7uncYTM50ttIjUTk0xIjC2IRYc&e=. |
INVITED MANUSCRIPT REVIEW ARTICLES (PEER REVIEWED): |
06/15/2010 Burke MJ. Recent Pharmacological Advances in the Treatment of Acute Lymphoblastic Leukemia. Clinical Medicine Insights: Therapeutics. 2010 June 15. |
07/05/2010 Verneris MR, Burke MJ. Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. Curr Hematol Malig Rep. 2010 Jul;5(3):157-62. Review. PubMed PMID: 20446122. |
01/2014 Thakar MS, Talano JM, Tower RL, Kelly ME, Burke MJ. Indications for Transplantation in Childhood Acute Leukemia and the Impact of Minimal Residual Disease on Relapse: A Review. Clinical Practice. January 2014. |
02/2014 Burke MJ. Profile of Imatinib in Pediatric Leukemia. Pediatric Health, Medicine and Therapeutics. February 2014. |
05/14/2014 Burke MJ, Bhatla T. Epigenetic Modifications in Pediatric Acute Lymphoblastic Leukemia. Frontiers in Pediatric Oncology Research. May 2014 |
07/2014 Burke MJ. How to Manage Asparaginase Hypersensitivity in Acute Lymphoblastic Leukemia. Future Oncology. 2014 Jul 1:1-13.[Epub ahead of print] PubMed PMID 24983955 |
11/30/2015 Erker C, Harker-Murray P, Burke MJ. Emerging Immunotherapy in Pediatric Lymphoma. Future Oncology. 2015 Nov 30. 12(2):257-70 PubMed PMID 26616565 |
04/2016 Burke MJ. Oncolytic Seneca Valley Virus (SVV-001): past perspectives and future directions. Oncolytic Virotherapy. Accepted April 2016 |
05/14/2016 Burke MJ, Bhatla T. Epigenetic Modifications in Pediatric Acute Lymphoblastic Leukemia. Frontiers in Pediatric Oncology Research. 2014 May 14;2:42 PubMed PMID 24860797 |
09/06/2016 Burke MJ. Oncolytic Seneca Valley Virus (SVV-001): past perspectives and future directions. Oncolytic Virotherapy. 2016 Sep 6;5:81-9. PubMed PMID 27660749 |
02/2017 - Present Bhatt BS, Phelan R, Burke MJ. Pediatric Acute Lymphoblastic Leukemia: The Role of Hematopoietic Stem-Cell Transplantation in First Remission. Submitted to Journal of Pediatrics Review, February 2017 |
03/2017 - Present Bhatt BS, Phelan R, Burke MJ. Pediatric Acute Lymphoblastic Leukemia: The Role of Hematopoietic Stem-Cell Transplantation in First Remission. Accepted to Journal of Pediatrics Review, March 2017 |
07/07/2017 Lamble A, Phelan R, Burke M. When Less is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia. J Clin Med. 2017 Jul 7;6(7). PubMed PMID 28686179. |
NATIONAL CHILDREN'S ONCOLOGY GROUP TRIALS (NOT SUPPORTED BY GRANT FUNDING): |
2010 - 2013 Children's Oncology Group (COG), COG AALL03B1:Classification of Acute Lymphoblastic Leukemia, UMN Institutional PI.
|
2010 - 2011 Children’s Oncology Group (COG) COG AALL0331: Standard Risk B-Precursor Acute Lymphoblastic Leukemia, Institutional PI
|
2010 - 2011 Children’s Oncology Group (COG)COG AALL07P4 A Pilot Study of Intravenous EZN-2285 (CS-PEG E. Coli L-Asparaginase, IND# 100594) or Intravenous Oncaspar in the Treatment of Patients with High-Risk Acute Lymphoblastic Leukemia (ALL), Institutional PI
|
2010 - 2011 Children’s Oncology Group (COG) COG AALL07P2 - Erwinia Asparaginase, Institutional PI
|
2010 - 2013 Children’s Oncology Group (COG):COG AAML0531, UMN Institutional PI
|
2010 - 2013 Children’s Oncology Group (COG) COG AAML0431: The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years, UMN Institutional PI
|
2010 - 2013 Children's Oncology Group (COG) COG AALL0434: Intensified Methotrexate, Nelarabine and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia, UMN Institutional PI. |
2010 - 2013 Children’s Oncology Group (COG) AALL06N1 A Study of Neurocognitive Function in Children Treated for ALL, UMN Institutional PI
|
2010 - 2013 Children’s Oncology Group (COG)COG AALL08B1: Classification of Acute Lymphoblastic Leukemia, UMN Institutional PI.
|
2010 - 2013 Children’s Oncology Group (COG) COG AALL0631: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807), UMN Institutional PI
|
2010 - 2011 Children’s Oncology Group (COG) COG AALL0232 High Risk B-precursor Acute Lymphoblastic Leukemia, Institutional PI
|
2010 - 2013 Children’s Oncology Group (COG)
COG AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Samples, UMN Institutional PI
|
2010 - 2013 Children’s Oncology Group (COG) COG AALL0433: Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies, UMN Institutional PI
|
2013 - 2015 Children’s Oncology Group (COG) COG AAML1321: A Multi-Center, Open Label, Non-Controlled Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients with Newly Diagnosed Ph+ CML in Chronic Phase (CP) or with Ph+ CML in CP or Accelerated Phase Resistant or Intolerant to either Imatinib or Dasatinib, CHW Institutional PI. |
2015 - 2019 Children’s Oncology Group (COG) COG AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumumab in 1st Relapse B-ALL, CHW Institutional PI.
|
2015 - Present Children’s Oncology Group (COG) COG AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolesents, CHW Institutional PI. |
2015 - 2019 Children’s Oncology Group (COG) COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib on an ABFM Backbone in Newly Diagnosed T-ALL and T-LL, CHW Institutional PI. |
2016 - Present Children’s Oncology Group (COG) COG AAML1531: Risk-stratified Therapy for AML in Down syndrome, CHW Institutional PI.
|
2016 - 2019 Children’s Oncology Group (COG) COG AAML1421: A Phase I/II Study of CPX-351 Alone Followed by FLAG for Children with Relapsed AML, CHW Institutional PI.
|
2016 - Present Children’s Oncology Group (COG) COG AAML1331: A Phase III Study for Patients with Newly Diagnosed APL Using Arsenic Trioxide and ATRA, CHW Institutional PI.
|
2017 - Present Children’s Oncology Group (COG) COG AALL1521: A Phase II Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway Mutant ALL, CHW Institutional PI.
|
2017 - 2019 Children’s Oncology Group (COG) COG AAML1522: A Phase II, Multicenter, Single-Arm, Open Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide in Pediatric Subjects Ages 1-18 years of Age with Relapsed or Refractory AML, CHW Institutional PI.
|
2018 - Present Children’s Oncology Group (COG) COG AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy, Study Committee Member |
NATIONAL CHILDREN'S ONCOLOGY GROUP TRIALS (SUPPORTED BY GRANT FUNDING) : |
2023 - Present Children’s Oncology Group (COG) COG ACCL1931: Randomized Trial of Levocarnitine
Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults
Newly Diagnosed with Acute Lymphoblastic Leukemia. Study Vice-Chair |
NATIONAL INVITED WEBINAR PRESENTATIONS: |
01/25/2011 Burke, Michael, “Oncolytic Virotherapy for Pediatric Tumors - Seneca Valley Virus”. National Webinar- Solving Kid’s Cancer, January 25, 2011.
|
01/26/2011 Burke, Michael,“Implications for Nursing Practice in Pediatric Leukemia.” National Webinar – The National Children’s Cancer Society, January 26, 2011. |
03/2014 Burke, Michael, “The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia.” National Webinar – JAZZ Pharmaceuticals, March 25, 2014 |
02/10/2015 “The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia.” Webinar. |
11/24/2015 “The Role of Erwinaze® (asparaginase Erwinia chrysanthemi) in the Treatment of Acute Lymphoblastic Leukemia.” Webinar. |
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M. Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. Pediatr Blood Cancer. 2007 Aug;49(2):196-8. PubMed PMID: 17417796. |
2. Burke MJ, Cohn SL. Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. Pediatr Blood Cancer. 2008 Mar;50(3):679-80. PubMed PMID: 16900484. |
3. Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Bone Marrow Transplant. 2009 Jan;43(2):107-13. PubMed PMID: 18776928. |
4. Burke MJ, Dayton V. Treatment of a CNS relapse while on therapy for Burkitt lymphoma. Pediatr Blood Cancer. 2009 Feb;52(2):290-2. PubMed PMID: 18937319. |
5. Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. Bone Marrow Transplant. 2009 Aug;44(3):169-74. PubMed PMID: 19204709. |
6. Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, Burke MJ, Blazar BR, Miller JS, McGlave PB, Weisdorf DJ, Wagner JE. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood. 2009 Nov 5;114(19):4293-9. PubMed PMID: 19706886 |
7. Burke MJ, Cao Q, Trotz B, Weigel B, Kumar A, Smith A, Verneris MR. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2009 Dec 15;53(7):1289-94. PubMed PMID: 19731318. |
8. Burke MJ, Willert J, Desai S, Kadota R. The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era. Pediatr Blood Cancer. 2009 Dec;53(6):992-5. PubMed PMID: 19621426. |
9. Beck JC, Burke MJ, Tolar J. Response of refractory immune thrombocytopenia after bone marrow transplantation to romiplostim. Pediatr Blood Cancer. 2010 Mar;54(3):490-1. PubMed PMID: 19908296. |
10. Verneris MR, Eapen M, Duerst R, Carpenter PA, Burke MJ, Afanasyev BV, Cowan MJ, He W, Krance R, Li CK, Tan PL, Wagner JE, Davies SM. Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2010 Sep;16(9):1237-44. PubMed PMID: 20302960. |
11. Shaw PJ, Kan F, Woo Ahn K, Spellman SR, Aljurf M, Ayas M, Burke M, Cairo MS, Chen AR, Davies SM, Frangoul H, Gajewski J, Gale RP, Godder K, Hale GA, Heemskerk MB, Horan J, Kamani N, Kasow KA, Chan KW, Lee SJ, Leung WH, Lewis VA, Miklos D, Oudshoorn M, Petersdorf EW, Ringdén O, Sanders J, Schultz KR, Seber A, Setterholm M, Wall DA, Yu L, Pulsipher MA. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood. 2010 Nov 11;116(19):4007-15. PubMed PMID: 20671124 |
12. Smith AR, Gulbahce E, Burke MJ, Cao Q, Macmillan ML, Tolar J, Orchard PJ, Blazar BR, Baker KS, Wagner JE, Verneris MR. Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant. Bone Marrow Transplant. 2011 Mar;46(3):368-71. PMID: 20548337. |
13. Bachanova V, Sandhu K, Yohe S, Cao Q, Burke MJ, Verneris MR, Weisdorf D. Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. Blood. 2011 May 12;117(19):5261-3. PubMed PMID: 21403127 |
14. Burke MJ, Vogel RI, Janardan SK, Brunstein C, Smith AR, Miller JS, Weisdorf D, Wagner JE, Verneris MR. Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. Biol Blood Marrow Transplant. 2011 Jun;17(6):831-40. PubMed PMID: 20831896. |
15. Beck JC, Cao Q, Trotz B, Smith AR, Weigel BJ, Verneris MR, Burke MJ. Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse. Bone Marrow Transplant. 2011 Jul;46(7):950-5. PMID: 20856210. |
16. Burke MJ, McCormack J, Qing Q, Verneris M. Allogeneic hematopoietic cell transplantation outcomes for children and young adults with treatment-related myelodysplastic syndrome or acute myeloid leukemia. Journal of Hematological Malignancies. 2011 December;Vol.1(1):6-14. |
17. Bhatla T, Wang J, Morrison DJ, Raetz EA, Burke MJ, Brown P, Carroll WL. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood. 2012 May 31;119(22):5201-10. PMID: 22496163 |
18. Bachanova V, Burke MJ, Yohe S, Cao Q, Sandhu K, Singleton TP, Brunstein CG, Wagner JE, Verneris MR, Weisdorf DJ. Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. Biol Blood Marrow Transplant. 2012 Jun;18(6):963-8. PubMed PMID: 22430088. |
19. Burke MJ, Lindgen B, Verneris MR. Treatment of relapsed acute lymphoblastic leukemia: approaches used by pediatric oncologists and bone marrow transplant physicians. Pediatr Blood Cancer. 2012 Jun;58(6):840-5. PubMed PMID: 21796765. |
20. Honebrink T, Dayton V, Burke MJ, Larsen K, Cao Q, Brunstein C, Weisdorf D, Miller JS, Wagner JE, Verneris MR. Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia. Biol Blood Marrow Transplant. 2012 Jun;18(6):930-6. PubMed PMID: 22108570. |
21. Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, Glade Bender J, Burke M, Weigel BJ, Stempak D, Balis FM, Blaney SM. A Phase I Trial and Pharmacokinetic Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children with Refractory Solid Tumors or Refractory Leukemias. Clin Cancer Res. 2012 Nov 1;18(21):6011-22. PubMed PMID: 22962440. |
22. Burke MJ, Gossai N, Wagner JE, Smith AR, Bachanova V, Cao Q, Macmillan ML, Stefanski HS, Weisdorf DJ, Verneris MR. Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2013 Jan; 19(1):138-42. PubMed PMID: 22960388. |
23. Smith AR, Christiansen EC, Wagner JE, Qing C, MacMillan ML, Stefanski HE, Trotz BA, Burke MJ, Verneris MR. Early Hematopoietic Stem Cell Transplant is Associated with Favorable Outcomes in Children with MDS. Pediatric Blood and Cancer 2013 Apr;60(4):705-10. PubMed PMID: 23152304. |
24. Burke MJ, Wagner JE, Cao Q, Ustun C, Verneris MR. Allogeneic Hematopoietic Cell Transplantation in First Remission Abrogates Poor Outcomes Associated with High-Risk Pediatric Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation 2013. Jul;19(7):1021-5 PubMed PMID: 23567175. |
25. Burke MJ, Burns L, Linden MA, Lindgren B, Verneris MR, Weisdorf D, Ustun C. How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. American Journal of Hematology 2013 Sept;88(9):826-7 PubMed PMID: 23737091. |
26. Ustun C, Wiseman AC, Defor TE, Yohe S, Linden MA, Oran B, Burke M, Warlick E, Miller JS, Weisdorf D. Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. Bone Marrow Transplantation 2013 Nov;48(11):1415-20. PubMed PMID 23933764 |
27. Burke MJ, Gossai N, Cao Q, MacMillan ML, Warlick E, Verneris MR. Similar outcomes between adolescent / young adults and children with AML following allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. 2014 Feb;49(2):174-8 PubMed PMID: 24185590. |
28. Pratt JA, Stricherz MK, Verghese PS, Burke MJ. Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population treated for neutropenic fever. Pediatric Blood and Cancer.2014 Feb;61(2):366-8 PubMed PMID 24038944. |
29. Gossai N, Verneris MR, Karras NA, Gorman MF, Patel NJ, Burke MJ. A clofarabine-based bridging regimen in patients with acute lymphoblastic leukemia (ALL) and persistent minimal residual disease (MRD). Bone Marrow Transplantation. 2014 Mar;49(3):440-2 PubMed PMID: 24317126. |
30. Burke MJ*, Lamba JK*, Pounds S, Cao X, Ghodke-Puranak Y, Lindgren BR, Weigel BJ, Verneris MR, Miller JS. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia (ALL). Am J Hematol. 2014 Sep;89(9):889-95. PubMed PMID 24891274. *authors contributed equally to the manuscript |
31. Burke MJ, Ahern C, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt MB, Blaney SM. Phase I trial of Seneca valley virus (NTX-010) in children with relapsed/refractory solid tumors: A report of the Children’s Oncology Group. Pediatric Blood and Cancer 2015 May;62(5):743-50. PubMed PMID 25307519 |
32. Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, Auletta JJ, Ayas M, Brown VI, Cairo MS, Chan KW, Diaz Perez MA, Dvorak CC, Egeler RM, Guilcher GMT, Hayashi RJ, Kasow KA, Leung WH, Olsson RF, Pulsipher MA, Shah NN, Thiel E, Kitko CL. Transplant Outcomes for Children with T-Cell Acute Lymphoblastic Leukemia in Second Remission: A Report of the CIBMTR®. Biology of Blood and Marrow Transplantation 2015 Dec;21(12):2154-9. PubMed PMID 26327632 |
33. Lu BY, Thanawala SU, Zochowski K, Burke MJ, Carroll WL, Bhatla T. Decitabine enhances chemosensitivity of ETP-ALL but no other T-ALL subtypes. Leukemia & Lymphoma - 2016 Jan 4:1-4 PubMed PMID: 26726842 |
34. Rodriguez V, Kairalla J, Salzer W, Raetz E, Loh M, Carroll A, Heerema NA, Wood B, Borowitz MJ, Burke MJ, Asselin B, Devidas M, Winick NW, Carroll WL, Hunger SP, Dreyer Z. A pilot study of intensified PEG-asparaginase in high risk acute lymphoblastic leukemia: Children’s Oncology Group Study AALL08P1. Journal of Pediatric Hematology-Oncology 2016 Aug;38(6):409-17. PubMed PMID: 27299599. |
35. Burke MJ and Rheingold SR. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for Acute Lymphoblastic Leukemia. Leukemia and Lymphoma 2016 Aug 22:1-12 PubMed PMID: 27546298 |
36. Burke MJ. Oncolytic Seneca Valley Virus: current perspectives. Oncolytic Virother. 2016 Sep 6;5:81-9 PubMed PMID 27660749 |
37. Gu Z, Li Y, Liu Y, Reshmi S, Roberts K, Harvey RC, McCastlain K, Payne-Turner D, Churchman M, Iacobucci I, Shao Y, Easton J, Chen I, Valentine M, Mungall K, Mungall A, Ma Y, Moore R, Marra M, Eileen Stonerock, Julie Gastier-Foster, Meenakshi Devidas, Yunfeng Dai, Brent Wood, Michael Borowitz, Eric Larsen, Maloney K, Mattano Jr LA, Angiolillo A, Salzer WL, Burke MJ, Rambaldi A, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger S, Bhatia R, Aldoss I, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Gerhard DS, Loh M, Hunger S, Mullighan C. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukemia. Nature Communications 2016 Nov 8;7:13331. PubMed PMID: 27824051 |
38. Sun W, Orgel E, Malvar J, Sposto R, Wilkes JJ, Gardner R, Pineros V, Smith A, Hur M, Hoffman J, Rheingold SR, Burke MJ, Wayne AS. Treatment Related Adverse Events Associated with a Modified UK ALLR3 Induction Chemotherapy Backbone for Childhood Relapsed/Refractory Acute Lymphoblastic Leukemia. Pediatric Blood and Cancer 2016 Nov;63(11):1943-8. PubMed PMID: 27437864 |
39. Burke MJ and Rheingold SR. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for Acute Lymphoblastic Leukemia. Leukemia and Lymphoma 2017 Mar;58(3):540-551. PubMed PMID: 27546298 |
40. Fisher JB, McNulty M, Burke MJ, Crispino J, Rao S. Cohesin Mutations in Myeloid Malignancies. Trends in Cancer. 2017 Apr;3(4):282-293. PubMed PMID 28626802 |
41. Robin AJ, Peterson JF, Grignon Jr. JW, Gheorghe G, Burke MJ, VanTuinen P. Identification of High-Risk Cryptic CRLF2 Rearrangements in B-cell Acute Lymphoblastic Leukemia Utilizing an FGFR3/IGH Dual-Color Dual-Fusion DNA Probe Set. Journal of Pediatric Hematology-Oncology 2017 May;39(4):e207-e210 PubMed PMID: 27820126 |
42. Reshmi S, Harvey R, Roberts KG, Stonerock E, Smith A, Jenkins H, Chen IM, Valentine M, Liu Y, Li Y, Shao Y, Easton J, Payne-Turner D, Tran TH, Nguyen JV, Devidas M, Dai Y, Heerema NA, Carroll AJ, Raetz EA, Borowitz MJ, Wood BL, Angiolillo AL, Burke MJ, Salzer WL, Zweilder-McKay, Rabin KR, Carroll WL, Zhang J, Loh ML, Mullighan CG, Willman CL, Gastier-Foster JM, Hunger SP. Targetable Kinase Gene Fusions in High Risk B-ALL: A Study from the Children’s Oncology Group. Blood 2017 Jun 22;129(25):3352-3361 PubMed PMID: 28408464 |
43. Schloemer NJ, Brickler M, Pan A, Hoffmann R, McFadden V, Block J, Tower RL, Burke MJ. Administration of Dexrazoxane Improves Cardiac Outcomes in Children and Young Adults with Acute Myeloid Leukemia (AML) While Maintaining Survival Outcomes. Journal of Pediatric Hematology/Oncology 2017 Jul;39(5):e254-e258 PMID: 28452856 |
44. Bhatt BS, Phelan R, Burke MJ. The Role of Hematopoietic Stem-Cell Transplantation in First Remission in Pediatric Acute Lymphoblastic Leukemia: A Narrative Review. Journal of Pediatrics Review. 2017 July;5(2):e10831. doi:10.5812/jpr.10831 |
45. Bhojwani D, Burke MJ, Horton T, Ziegler DS, Sulis ML, Schultz KR, Wayne A, Izraeli S, Chang BH. Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group. Pediatric Hematol Oncol 2017 Nov 30:1-10 PubMed PMID:29190164 |
46. Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, Borowitz M, Wood B, Heerema NA, Carroll AJ, Hilden JM0, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Toxicity Associated with Intensive Post-Induction Therapy Incorporating Clofarabine in the Very High-Risk Stratum of Patients with Newly Diagnosed High Risk B-Lymphoblastic Leukemia: A Report from the Children’s Oncology Group Study AALL1131. Cancer 2018 Mar 15;124(6):1150-1159 PMID: 29266189 *These 2 authors contributed equally as first authors |
47. Roberts KG, Reshmi SC, Harvey RC, Chen I, Patel K, Stonerock E, Jenkins H, Dai Y, Valentine M, Gu Z, Zhao Y, Liu Y, Li Y, Zhang J, Payne-Turner D, Devidas M, Heerema NA, Carroll AJ, Raetz EA, Borowitz MJ, Wood BL, Angiolillo A, Burke MJ, Salzer WL, Zweidler-McKay PA, Rabin KR, Mattano L, Maloney KW, Carroll WL, Loh ML, Mullighan CG, Willman CL, Gastier-Foster JM, Hunger SP. Genomic and outcome analyses of Philadelphia chromosome-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group. Blood. 2018 Aug 23;132(8):815-824 PMID: 29997224 |
48. Schulte RR, Madiwale MV, Flower A, Hochberg J, Burke MJ, McNeer J, Duvall A, Bleyer A. Levocarnitine for Asparaginase-Induced Hepatic Injury: A Multi-Institutional Case Series and Review of the Literature. Leukemia & Lymphoma 2018 Oct;59(10):2360-2368 PMID: 29431566 |
49. Becktell K, Houser K, Burke MJ. Epigenetic therapy in a patient with Down syndrome and refractory acute myeloid leukemia. Journal of Pediatric Hem Onc. 2019 Jan;41(1):e38-e40 PMID: 29668549 |
50. Broglie L, Gershan J, Burke MJ. Check-point inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia. International Int J Hematol Oncol. 2019 Jan 16;8(1):IJH10 PMID: 30863527 |
51. Andolina JR, Burke MJ, Hijiya N, Chaudhury S, Schultz KR, Roth ME. Practice Patterns of Physician Treatment for Pediatric Chronic Myeloid Leukemia (CML). Biol Blood Marrow Transplant. 2019 Feb;25(2):321-327 PMID: 30267760 |
52. Lu BY, Thanawala SU, Zochowski K, Burke MJ, Carroll WL, Bhatla T. Decitabine enhances chemosensitivity of ETP-ALL but no other T-ALL subtypes. British Journal of Haematology Submitted July 2015 |
53. Burke MJ, Devidas M, Maloney K, Angiolillo A, Schore R, Dunsmore K, Larsen E, Leonard A. Mattano Jr LA., Salzer W, Winter SS, Carroll W, Winick NJ, Loh ML, Raetz E, Hunger SP, Bleyer A. Pegaspargase Hypersensitivity Reaction Rates with Intravenous Infusion versus Intramuscular Injection: Analysis of 34,413 Doses Administered to 16,534 Patients on Children’s Oncology Group (COG) Clinical Trials. Submitted to Journal of Clinical Oncology August 2016 (under revision for submission to Cancer) |
54. Pommert L, Margossian S, Burke MJ. Critical care of the pediatric immunocompromised hematology/oncology patient: an evidence-based guide. Text Book; Chapter submitted on Acute Leukemia. February 2018 |
55. Keating A, Gossai N, Phillips C, Maloney K, Doan A, Bhojwani D, Burke MJ, Verneris MR. Reducing Minimal Residual Disease Prior to Hematopoietic Cell Transplant for Pediatric Patients with Acute Lymphoblastic Leukemia. Accepted to Blood Advances December 2018 |
56. Taraseviciute A, Broglie L, Phelan R, Bhatt N, Becktell K, Burke MJ. What is the role of hematopoietic cell transplantation for pediatric acute lymphoblastic leukemia in the age of chimeric antigen receptor T-cell therapy? Accepted to Journal of Pediatric Hematology/Oncology December 2018 |
57. Athale U, Hijiya N, Patterson B, Bergsagel DJ, Andolina J, Bittencourt H, Schultz K, Burke M, Redell M, Kolb E, Johnston D. Management of chronic myeloid leukemia (CML) in children and adolescents: Recommendations from the Children’s Oncology Group CML Working Group. Accepted to Pediatric Blood and Cancer March 2019 |
58. Taraseviciute A, Broglie L, Phelan R, Bhatt N, Becktell K, Burke MJ. What is the role of hematopoietic cell transplantation for pediatric acute lymphoblastic leukemia in the age of chimeric antigen receptor T-cell therapy? J Pediatr Hematol Oncol. 2019 Apr 9 [Epub ahead of print] PubMed PMID: 30973486 |
59. Salzer WL, Burke MJ, Devidas M, Dai Y, Hardy KK, Kairalla JA, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, Winick N, Carroll WL, Raetz EA, Loh ML, Hunger SP. Impact of intrathecal triple therapy versus intrathecal methotrexate on disease free survival for high risk B-lymphoblastic leukemia: Children’s Oncology Group study AALL1131. Accepted to Journal of Clinical Oncology February 2020 |
60. Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PA. Decitabine and vorinostat with chemotherapy in relapsed pediatric acute lymphoblastic leukemia: A TACL pilot study. Clin Cancer Res. 2020 Jan 22 [Epub ahead of print] |
61. Rossoff J, Huynh V, Rau RR, Macy ME, Sulis ML, Schultz KR, Burke MJ, Athale U, O’Brien MM, Gregory JJ, Van der Sluis IM, Keller FG, Zwaan CM, Suttorp M, Hijiya N. Experience with ponatinib in pediatric patients with leukemia. Br J Haematol.2020 Apr; 189(2):363-368. Doi: 10.1111/bjh.16338. PMID: 31975387 |
62. Salzer WL, Burke MJ, Devidas M, Dai Y, Hardy KK, Kairalla JA, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, Winick N, Carroll WL, Raetz EA, Loh ML, Hunger SP. Impact of intrathecal triple therapy versus intrathecal methotrexate on disease free survival for high risk B-lymphoblastic leukemia: Children’s Oncology Group study AALL1131. J Clin Oncol. 2020 Jun 4:JCO1902892 [Epub ahead of print] PMID: 32496902 |
63. Yu Q, Zhong X, Chen B, Feng Y, Ma M, Diamond CA, Voeller JS, Kim M, DeSantes KB, Capitini C, Patel N, Hoover-Regan M, Burke MJ, Janko K, Puccetti DM, Ikonomidou C, Li L. Isobaric labeling strategy utilizing 4-plex N, N-dimethyl leucine (DiLeu) tags reveals proteomic changes induced by chemotherapy in cerebrospinal fluid of children with B-cell acute lymphoblastic leukemia. J Proteome Res. 2020 May 27 [Epub ahead of print] PMID: 32396724 |
64. John Goldberg, Julia Bender, Sima Jeha, Maria Luisa Sulis, Rebecca Gardner, Jessica Pollard, Victor Aquino, Theodore Laetsch, Naomi Winick, Cecilia Fu, Leigh Marcus, Weili Sun, Anupam Verma, Michael Burke, Phoenix Ho, Thomas Manley, Rajen Mody, Wendy Tcheng, Blythe Thomson, Julie Park, Richard Sposto, Yoav Messinger, Nobuko Hijiya, Paul Gaynon, Julio Barredo. A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies. Pediatric Hematology and Oncology. 27 April 2020 [Epub ahead of print] |
65. Pommert L, Liberio N, Ng JS, Egelund TA, Siver MJ, Katzenstein HM, Burke MJ. Concurrent imatinib dosing with high-dose methotrexate clearance in pediatric patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2020 May 8 [Epub ahead of print] PMID: 32398599 |
66. Pommert L, Burns R, Furumo Q, Pulakanti K, Brandt J, Burke MJ, Rao S. Novel germline TRAF3IP3 mutation in a dyad with familial acute B lymphoblastic leukemia. Accepted in Cancer Reports December 2020 |
67. Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Winge BA, Cooper TM, Pauly M, Maloney K, Burke MJ, Brown P, Gossai N, McNeer J, Shukla N, Cole P, Kahn J Chen J, Barth M, Magee J, Gennarini L, Adhav AA, Clinton C, Ocasio-Martinez N, Gotti G, Li Y, Lin S, Inamovic A, Tognon CE, Patel T, Faust HL, Contreras C, Cremer A, Cortopassi WA, Ruiz DG, Jacobsen MP, Dharia NV, Su A, Robichaud AL, Conway AS, Tarlock K, Stieglitz E, Place AE, Puissant A, Hunger SP, Kim AS, Lindeman NI, Gore L, Janeway K, Silverman LB, Tyner JW, Harris MH, Loh ML, Stegmaier K. Matched targeted therapy for pediatric patients with relapsed, refractory of high-risk leukemias: A report from the LEAP consortium. Accepted in Cancer Discovery December 2020 |
68. Rau R, Dai Y, Devidas M, Rabin K, Zweidler-McKay P, Angiolillo A, Schore R, Burke M, Salzer W, Heerema N, Carroll A, Winick N, Hunger S, Raetz E, Loh M, Wood B, Borowitz M. Prognostic impact of minimal residual disease at end of consolidation in NCI standard risk B-lymphoblastic leukemia: A report from the Children’s Oncology Group. Accepted in Pediatric Blood and Cancer January 2021 |
69. Brady SW, Roberts KG, Zhaohui G, Shi L, Pounds S, Pei D, Cheng C, Dai Y, Devidas M, Qu C, Hill AN, Payne-Turner D, Ma X, Wei L, Arunachalam S, Hagiwara K, Liu Y, Flasch D, Liu Y, Parker M, Chen X, Li Y, Fan Y, Michael JR, Rusch M, Wilkinson MR, Foy S, Hedges D, Newman S, Zhou X, Wang J, Sioson E, Rice SV, Pastor V, Wu G, Rampersaud E, Rshmi SC, Gastier-Foster J, Guidry-Auvil J, Gesuwan P, Smith MA, Winick N, Carroll AJ, Heerema N, Harvey RC, Willman CL, Larsen E, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Winter SS, Burke MJ, Salzer W, Dunsmore KP, Angiolillo AL, Crews K, Downing JR, Jeha S, Pui CH, Evans WE, Yang J, Relling MV, Gerhard DS, Loh ML, Hunger SP, Zhang J, Mullighan C. The genomic landscape of pediatric acute lymphoblastic leukemia. Submitted to Nature 2021 |
70. Rau R, Dai Y, Devidas M, Rabin K, Zweidler-McKay P, Angiolillo A, Schore R, Burke M, Salzer W, Heerema N, Carroll A, Winick N, Hunger S, Raetz E, Loh M, Wood B, Borowitz M. Prognostic impact of minimal residual disease at end of consolidation in NCI standard risk B-lymphoblastic leukemia: A report from the Children’s Oncology Group. Pediatric Blood and Cancer 2021 Apr;68(4):e28929 PMID:3355936 |
71. Pommert L, Burns R, Furumo Q, Pulakanti K, Brandt J, Burke MJ, Rao S. Novel germline TRAF3IP3 mutation in a dyad with familial acute B lymphoblastic leukemia. Cancer Reports (Hoboken) 2021 Jan 27:e1335 PMID: 33503336 |
72. Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Winge BA, Cooper TM, Pauly M, Maloney K, Burke MJ, Brown P, Gossai N, McNeer J, Shukla N, Cole P, Kahn J Chen J, Barth M, Magee J, Gennarini L, Adhav AA, Clinton C, Ocasio-Martinez N, Gotti G, Li Y, Lin S, Inamovic A, Tognon CE, Patel T, Faust HL, Contreras C, Cremer A, Cortopassi WA, Ruiz DG, Jacobsen MP, Dharia NV, Su A, Robichaud AL, Conway AS, Tarlock K, Stieglitz E, Place AE, Puissant A, Hunger SP, Kim AS, Lindeman NI, Gore L, Janeway K, Silverman LB, Tyner JW, Harris MH, Loh ML, Stegmaier K. Matched targeted therapy for pediatric patients with relapsed, refractory of high-risk leukemias: A report from the LEAP consortium. Cancer Discovery 2021 Jun;11(6):1424-1439. PMID:33563661 |
73. Schulte R, Hinson A, Huynh V, Breese E, Pierro J, Roth S, Mixon B, McNeer J, Burke M, Orgel E. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. Accepted to Cancer Medicine July 2021 |
74. Schulte R, Hinson A, Huynh V, Breese E, Pierro J, Roth S, Mixon B, McNeer J, Burke M, Orgel E. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. Accepted to Cancer Medicine August 2021 |
75. Burke MJ, Ziegler DS, Bautista F, Attarbaschi A, Gore L, Locatelli F, O’Brien MM, Pauly M, Kormany WN, Tian S, Morris CL, Baruchel A. Phase Ib Study of Carfilzomib with Induction Chemotherapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia. Submitted to Blood January 2022 |
76. Pommert L, Schafer ES, Malvar J, Florendo E, Gossai N, Pulakanti K, Heimbruch K, Stelloh C, Chi Y, Sposto R, Rao S, Huynh V, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan JA, Mody R, O’Brien TA, Place AE, Shaw PH, Ziegler DS, Wayne A, Bhojwani D, Burke MJ. Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the TACL Consortium. Submitted to Leukemia December 2021 |
77. Burke MJ and Zalewska-Szewczyk B. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: Immunology and clinical consequences. Accepted to Future Oncology December 2021 |
78. Burke MJ and Zalewska-Szewczyk B. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: Immunology and clinical consequences. Accepted to Future Oncology December 2021 |
79. Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SL, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Bhojwani D, Burke MJ. Real world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat and FLAG therapy based on a phase 1 study run by the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium. Submitted to American Journal of Hematology February 2022 |
80. Pommert L, Schafer ES, Malvar J, Florendo E, Gossai N, Pulakanti K, Heimbruch K, Stelloh C, Chi Y, Sposto R, Rao S, Huynh V, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan JA, Mody R, O’Brien TA, Place AE, Shaw PH, Ziegler DS, Wayne A, Bhojwani D, Burke MJ. Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the TACL Consortium. Accepted to American Journal of Hematology February 2022 |
81. Burke MJ and Zalewska-Szewczyk B. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: Immunology and clinical consequences. Future Oncology 2022 Feb 2. Doi:10.2217/fon-2021-1288. [online ahead of print] PMID: 35107320 |
82. Pasupuleti SK, Chao K, Ramdas B, Stieglitz E, Kapur R, Burke MJ. MEK inhibition in combination with 5-azacitidine rescues Shp2-driven Juvenile myelomonocytic leukemia. Submitted to Blood March 2022. |
83. Pommert L, Schafer ES, Malvar J, Florendo E, Gossai N, Pulakanti K, Heimbruch K, Stelloh C, Chi Y, Sposto R, Rao S, Huynh V, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan JA, Mody R, O’Brien TA, Place AE, Shaw PH, Ziegler DS, Wayne A, Bhojwani D, Burke MJ. Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the TACL Consortium. Am J Hematol 2022 Feb 18 doi: 10.1002/ajh.26510. [online ahead of print] PMID: 35180323 |
84. Pommert L, Schafer ES, Malvar J, Florendo E, Gossai N, Pulakanti K, Heimbruch K, Stelloh C, Chi Y, Sposto R, Rao S, Huynh V, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan JA, Mody R, O’Brien TA, Place AE, Shaw PH, Ziegler DS, Wayne A, Bhojwani D, Burke MJ. Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the TACL Consortium. Am J Hematol 2022 Feb 18 doi: 10.1002/ajh.26510. [online ahead of print] PMID: 35180323 |
85. Gupta S, Dai Y, Chen Z, Winestone L, Teachey DT, Bona K, Aplenc R, Rabin KR, Zweidler-McKay P, Carroll AJ, Heerema NA, Gastier-Foster J, Borowitz MJ, Wood BL, Maloney KW, Mattano Jr. LA, Larsen EC, Angiolillo AL, Burke MJ, Salzer WL, Winter SS, Brown PA, Guset EM, Dunsmore KP, Kairalla JA, Winick NJ, Carroll WL, Raetz EA, Hunger SP, Loh ML, Devidas M. Racial and ethnic disparities in outcome among children with acute lymphoblastic leukemia are not fully attenuated by disease prognosticators or insurance status: a Children’s Oncology Group (COG) study. Submitted to JCO April 2022 |
86. Brady SW, Roberts KG, Zhaohui G, Shi L, Pounds S, Pei D, Cheng C, Dai Y, Devidas M, Qu C, Hill AN, Payne-Turner D, Ma X, Wei L, Arunachalam S, Hagiwara K, Liu Y, Flasch D, Liu Y, Parker M, Chen X, Li Y, Fan Y, Michael JR, Rusch M, Wilkinson MR, Foy S, Hedges D, Newman S, Zhou X, Wang J, Sioson E, Rice SV, Pastor V, Wu G, Rampersaud E, Rshmi SC, Gastier-Foster J, Guidry-Auvil J, Gesuwan P, Smith MA, Winick N, Carroll AJ, Heerema N, Harvey RC, Willman CL, Larsen E, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Winter SS, Burke MJ, Salzer W, Dunsmore KP, Angiolillo AL, Crews K, Downing JR, Jeha S, Pui CH, Evans WE, Yang J, Relling MV, Gerhard DS, Loh ML, Hunger SP, Zhang J, Mullighan C. The genomic landscape of pediatric acute lymphoblastic leukemia. Accepted Nature Genetics March 2022 |
87. Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SL, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Bhojwani D, Burke MJ. Real world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat and FLAG therapy based on a phase 1 study run by the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium. Accepted Pediatric Blood and Cancer May 2022 |
88. Hardy KK, Kairalla JA, Gioia AR, Weisman HS, Gurung M, Noll RB, Hinds PS, Hibbitts E, Salzer W, Burke MJ, Winick NJ, Embry L. Impaired Neurocognitive Functioning 3 Months Following Diagnosis of High-Risk Acute Lymphoblastic Leukemia (ALL): A Report from the Children’s Oncology Group (COG). Submitted to JCO June 2022 |
89. Gossai NP, Devidas M, Chen Z, Wood BL, Zweidler-McKay PA, Rabin KR, Loh ML, Raetz EA, Winick NJ, Burke MJ, Carroll AJ, Esiashvili N, Heerema NA, Carrol WL, Hunger SP Dunsmore KP, Winter SS, Teachey DT. Prognostic Impact of Central Nervous System Status in T-Cell Acute Lymphoblastic Leukemia: A Report from Children’s Oncology Group. Submitted to JCO June 2022 |
90. Burke MJ, Ziegler DS, Bautista F, Attarbaschi A, Gore L, Locatelli F, O’Brien MM, Pauly M, Kormany WN, Tian S, Morris CL, Baruchel A. Phase Ib Study of Carfilzomib with Induction Chemotherapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia. Accepted to Pediatric Blood and Cancer July 2022 |
91. Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SL, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Bhojwani D, Burke MJ. Real world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat and FLAG therapy based on a phase 1 study run by the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium. Accepted Pediatric Blood and Cancer May 2022 |
92. Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SL, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Bhojwani D, Burke MJ. Real world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat and FLAG therapy based on a phase 1 study run by the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium. Pediatric Blood and Cancer June 21 2022, e29812. doi: 10.1002/pbc.29812. Online ahead of print. 35726826 |
93. Paolino J, Dimitrov B, Winger BA, Sandoval A, Ocasio-Martinez N, Tsai H, Li Y, Robichaud AL, Khalid D, Hatton C, Gillani R, Dilig A, Gotti G, Kavanagh J, Adhav AA, Tsai J, Li YD, Ebert BL, Van Allen EM, Bledsoe J, Kim AS, Burke MJ, Luskin M, Mar BG, Jacobson MP, Harris MH, Stegmaier K, Place AE, Pickman Y. Integration of genomic sequencing drives therapeutic targeting of PDGFRA in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. Submitted to Pediatric Blood and Cancer August 2022 |
94. Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SL, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Bhojwani D, Burke MJ. Real world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat and FLAG therapy based on a phase 1 study run by the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium. Pediatric Blood and Cancer June 21 2022, e29812. doi: 10.1002/pbc.29812. Online ahead of print. 35726826 |
95. Place AE, Blonquist T, Stevenson K, Hunt S, Cronholm S, McGraw L, Orloff-Parry S, Dabek R, Stieglitz E, Cooper TM, Gore L, Aplenc R, Loh ML, Pauly M, Rau RE, Burke MJ, Etchin J, Look AT, Sulis ML, Pikman Y, Silverman LB. Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia. Submitted to October 2022 |
96. Gossai N, Bhojwani D, Schafer ES, Chang BH, Pommert L, Verma A, Malvar J, Chi YY, Hitzler J, Burke MJ, Rabin K. Response to epigenetic therapy in relapsed myeloid leukemia of Down Syndrome: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium. Submitted to Leukemia October 2022 |
97. Gupta S, Dai Y, Chen Z, Winestone L, Teachey DT, Bona K, Aplenc R, Rabin KR, Zweidler-McKay P, Carroll AJ, Heerema NA, Gastier-Foster J, Borowitz MJ, Wood BL, Maloney KW, Mattano Jr. LA, Larsen EC, Angiolillo AL, Burke MJ, Salzer WL, Winter SS, Brown PA, Guset EM, Dunsmore KP, Kairalla JA, Winick NJ, Carroll WL, Raetz EA, Hunger SP, Loh ML, Devidas M. Racial and ethnic disparities in outcome among children with acute lymphoblastic leukemia are not fully attenuated by disease prognosticators or insurance status: a Children’s Oncology Group (COG) study. Accepted to Lancet Haematology November 2022 |
98. Gossai NP, Devidas M, Chen Z, Wood BL, Zweidler-McKay PA, Rabin KR, Loh ML, Raetz EA, Winick NJ, Burke MJ, Carroll AJ, Esiashvili N, Heerema NA, Carrol WL, Hunger SP Dunsmore KP, Winter SS, Teachey DT. Prognostic Impact of Central Nervous System Status in T-Cell Acute Lymphoblastic Leukemia: A Report from Children’s Oncology Group. Accepted in Blood November 2022 |
99. Burke MJ, Ziegler DS, Bautista F, Attarbaschi A, Gore L, Locatelli F, O’Brien MM, Pauly M, Kormany WN, Tian S, Morris CL, Baruchel A. Phase Ib Study of Carfilzomib with Induction Chemotherapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia. Pediatric Blood and Cancer 2022 Dec; 69(12):e29999. Doi10.1002/pbc.29999.Epub 2022 Oct 10. PMID:36215217 |
100. Brady SW, Roberts KG, Zhaohui G, Shi L, Pounds S, Pei D, Cheng C, Dai Y, Devidas M, Qu C, Hill AN, Payne-Turner D, Ma X, Wei L, Arunachalam S, Hagiwara K, Liu Y, Flasch D, Liu Y, Parker M, Chen X, Li Y, Fan Y, Michael JR, Rusch M, Wilkinson MR, Foy S, Hedges D, Newman S, Zhou X, Wang J, Sioson E, Rice SV, Pastor V, Wu G, Rampersaud E, Rshmi SC, Gastier-Foster J, Guidry-Auvil J, Gesuwan P, Smith MA, Winick N, Carroll AJ, Heerema N, Harvey RC, Willman CL, Larsen E, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Winter SS, Burke MJ, Salzer W, Dunsmore KP, Angiolillo AL, Crews K, Downing JR, Jeha S, Pui CH, Evans WE, Yang J, Relling MV, Gerhard DS, Loh ML, Hunger SP, Zhang J, Mullighan C. The genomic landscape of pediatric acute lymphoblastic leukemia. Nature Genetics 2022 Sep;54(9):1376-1389. PMID 3605048 |
101. Hardy KK, Kairalla JA, Gioia AR, Weisman HS, Gurung M, Noll RB, Hinds PS, Hibbitts E, Salzer W, Burke MJ, Winick NJ, Embry L. Impaired Neurocognitive Functioning 3 Months Following Diagnosis of High-Risk Acute Lymphoblastic Leukemia (ALL): A Report from the Children’s Oncology Group (COG). Accepted to PBC December 2022 |
102. Karen R Rabin, Meenakshi Devidas, Zhiguo Chen, Yunfeng Dai, Lingyun Ji, Johann K Hitzler, Jun Yang, Andrew J Carroll, Nyla A Hereema, Michael J Borowitz, Brent L Wood, Kathryn G Roberts, Charles G Mullighan, Richard Harvey, I-Ming Chen, Cheryl L Willman, Shalini Reshmi, Julie Gastier-Foster, Deepa Bhojwani, Susan R Rheingold, Kelly W Maloney, Eric C Larsen, Reuven J Schore, Michael J Burke, Wanda L Salzer, Naomi J Winick, William L Carroll, Elizabeth A Raetz, Mignon L Loh, Stephen P Hunger MD, Anne L Angiolillo. Outcomes in children, adolescents, and young adults with Down syndrome and acute lymphoblastic leukemia: A report from the Children’s Oncology Group. Submitted to New England Journal of Medicine January 2023 |
103. Ti-Cheng Chang*, Wenan Chen*, Chunxu Qu, Zhongshan Cheng, Dale Hedges, Abdelrahman Elsayed, Stanley B. Pounds, Mary Shago, Karen R. Rabin, Elizabeth A. Raetz, Meenakshi Devidas, Cheng Cheng, Anne Angiolillo, Michael Borowitz, Michael J. Burke, Andrew Carroll, William Carroll, I-Ming Chen, Richard Harvey, Nyla Heerema, Sima Jeha, Eric Larsen, Leonard Mattano, Kelly Maloney, Ching-Hon Pui, Nilsa C, Ramirez, Wanda Salzer, Cheryl Willman, Naomi Winick, Brent Wood, Stephen P. Hunger, Gang Wu, Charles G. Mullighan, Mignon L. Loh. Genomic Determinants of Outcome in Children with Standard Risk B-Progenitor Acute Lymphoblastic Leukemia. Submitted to New England Journal of Medicine January 2023 |
104. Gossai N, Bhojwani D, Schafer ES, Chang BH, Pommert L, Verma A, Malvar J, Chi YY, Hitzler J, Burke MJ, Rabin K. Response to epigenetic therapy in relapsed myeloid leukemia of Down Syndrome: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium. Accepted to Leukemia January 2023. |
105. Gossai N, Bhojwani D, Schafer ES, Chang BH, Pommert L, Verma A, Malvar J, Chi YY, Hitzler J, Burke MJ, Rabin K. Response to epigenetic therapy in relapsed myeloid leukemia of Down Syndrome: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium. Leukemia 2023 May;37(5):1138-1140. doi: 10.1038/s41375-023-01856-6. Epub 2023 Feb 22 |
106. Pasupuleti SK, Chao K, Ramdas B, Stieglitz E, Kapur R, Burke MJ. MEK inhibition in combination with 5-azacitidine rescues Shp2-driven Juvenile myelomonocytic leukemia. Mol Ther 2023 Apr 5;31(4):986-1001. doi: 10.1016/j.ymthe.2023.01.030. Epub 2023 Feb 3 |
107. Paolino J, Dimitrov B, Winger BA, Sandoval A, Ocasio-Martinez N, Tsai H, Li Y, Robichaud AL, Khalid D, Hatton C, Gillani R, Dilig A, Gotti G, Kavanagh J, Adhav AA, Tsai J, Li YD, Ebert BL, Van Allen EM, Bledsoe J, Kim AS, Burke MJ, Luskin M, Mar BG, Jacobson MP, Harris MH, Stegmaier K, Place AE, Pickman Y. Integration of genomic sequencing drives therapeutic targeting of PDGFRA in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. Submitted to Clinical Cancer Research April 2023 |
108. Paolino J, Dimitrov B, Winger BA, Sandoval A, Ocasio-Martinez N, Tsai H, Li Y, Robichaud AL, Khalid D, Hatton C, Gillani R, Dilig A, Gotti G, Kavanagh J, Adhav AA, Tsai J, Li YD, Ebert BL, Van Allen EM, Bledsoe J, Kim AS, Burke MJ, Luskin M, Mar BG, Jacobson MP, Harris MH, Stegmaier K, Place AE, Pickman Y. Integration of genomic sequencing drives therapeutic targeting of PDGFRA in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. Accepted to Clinical Cancer Research August 2023 |
109. Karen R Rabin, Meenakshi Devidas, Zhiguo Chen, Yunfeng Dai, Lingyun Ji, Johann K Hitzler, Jun Yang, Andrew J Carroll, Nyla A Hereema, Michael J Borowitz, Brent L Wood, Kathryn G Roberts, Charles G Mullighan, Richard Harvey, I-Ming Chen, Cheryl L Willman, Shalini Reshmi, Julie Gastier-Foster, Deepa Bhojwani, Susan R Rheingold, Kelly W Maloney, Eric C Larsen, Reuven J Schore, Michael J Burke, Wanda L Salzer, Naomi J Winick, William L Carroll, Elizabeth A Raetz, Mignon L Loh, Stephen P Hunger MD, Anne L Angiolillo. Outcomes in children, adolescents, and young adults with Down syndrome and acute lymphoblastic leukemia: A report from the Children’s Oncology Group. Accepted to JCO August 2023 |
110. Graff Z, Burke MJ, Gossai N. Novel therapies for pediatric acute lymphoblastic leukemia. Current Opinions in Pediatrics. Submitted September 5, 2023 |
111. Tager JB, Palou-Torres A, Bingen KM, Hoag JA, Burke MJ, Zhang J, Yan K, Karst JS. Health-Related Quality of Life among pediatric patients with Acute Lymphoblastic Leukemia: An exploratory cross-sectional study. Submitted to Pediatric Blood and Cancer November 2023 |
112. Graff Z, Burke MJ, Gossai N. Novel therapies for pediatric acute lymphoblastic leukemia. Current Opinions in Pediatrics. 2023 Nov 23. Doi: 10.1097/MOP.0000000000001316. Online ahead of print. |
113. Rabin KR, Devidas M, Chen Z, Dai Y, Ji L, Hitzler JK, Yang J, Carroll AJ, Hereema NA, Borowitz MJ, Wood BL, Roberts KG, Mullighan CG, Harvey R, Chen IM, Willman CL, Reshmi S, Gastier-Foster J, Bhojwani D, Rheingold SR, Maloney KW, Larsen EC, Schore RJ, Burke MJ, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Loh ML, Hunger SP, Angiolillo AL. Outcomes in children, adolescents, and young adults with Down syndrome and acute lymphoblastic leukemia: A report from the Children’s Oncology Group. J Clin Oncol. 2023 Oct 27:JCO2300389. Doi: 10.1200/JCO.23.00389. Online ahead of print |
114. Paolino J, Dimitrov B, Winger BA, Sandoval A, Ocasio-Martinez N, Tsai H, Li Y, Robichaud AL, Khalid D, Hatton C, Gillani R, Dilig A, Gotti G, Kavanagh J, Adhav AA, Tsai J, Li YD, Ebert BL, Van Allen EM, Bledsoe J, Kim AS, Burke MJ, Luskin M, Mar BG, Jacobson MP, Harris MH, Stegmaier K, Place AE, Pickman Y. Integration of genomic sequencing drives therapeutic targeting of PDGFRA in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. Clinical Cancer Res. 2023 Nov 14;29(22):4613-4626 |
115. DelRocco NJ, Loh ML, Borowitz MJ, Gupta S, Rabin KR, Zweidler-McKay P, Maloney KW, Mattano LA, Larsen E1, Angiolillo A, Schore RJ, Burke MJ, Salzer WL, Wood BL, Carroll AJ, Heerema NA, Reshmi SC, Gastier-Foster JM, Harvey R, Chen IM, Roberts KG, Mullighan CG, Willman C, Winick N, Carroll WL, Rau RE, Teachey DT, Hunger SP, Raetz EA, Devidas M, Kairalla JA. Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children’s Oncology Group Report. Accepted to Leukemia January 2024 |
Books, Chapters, and Reviews |
1. Chronic Myeloid Leukemia: From Daily Management to Complicated Issues. Chapter IV: CML in the
Pediatric Population. Burke M and Eldjerou L. Nova Science Publishers, Inc. 2013.
|
Editorials, Letters to Editor, Other |
1. Beck JC, Cao Q, Trotz B, Smith AR, Weigel BJ, Verneris MR, Burke MJ. Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse. Bone Marrow Transplant. 2011 Jul;46(7):950-5. PubMed PMID: 20856210. |
2. Burke MJ. Allogeneic hematopoietic cell transplantation provides no benefit for patients with hypodiploidy acute lymphoblastic leukemia. J Clin Oncol. 2019 Apr 1;37(10):763-764 PMID: 30794478 |
Abstracts |
1. Burke MJ, Kletzel M, Jacobsohn DA, Duerst RE. Tandem High-Dose Chemotherapy with Peripheral Blood Stem Cell Rescue as Consolidation Therapy for High-Risk (Primary Unresectable Pelvic Tumors or Metastatic Disease) Ewing's Sarcoma Patients Compared to Standard Chemotherapy. ASBMT Annual Meeting. Biology of Blood and Marrow Transplantation February 2005; Vol.11, Issue 2, Supplement 1:85. |
2. Burke MJ, Kennedy P, Wang L, Bhatt D, Tse WT. Myogenic Developmental Potential of Hemangioblasts Derived From Mouse Embryonic Stem Cells. American Society of Hematology (ASH) Annual Meeting. Blood November 2005; Vol. 106, Issue 11: 1702. |
3. Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR. Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Impact of Imatinib on Cardiac Toxicity, Relapse and Survival. ASBMT Annual Meeting. Biology of Blood and Marrow Transplantation February 2008; Vol.14, Issue 2, Supplement: 56-57. |
4. Burke MJ, Gursahaney A, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR. Cardiac risks of imatinib in chronic myelogenous leukemia (CML) patients who receive allogeneic hematopoietic cell transplantation (Allo-HCT). ASCO Annual Meeting. Journal of Clinical Oncology May 2008, 26: 7039. |
5. Burke MJ, Trotz B, Cao Q, Weigel B, Kumar A, Smith A, Verneris MR. Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) for Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (ALL). American Society of Hematology (ASH) Annual Meeting. Blood November 2009, Vol.114, Issue 22: 3377. |
6. Burke MJ, Lamba J, Weigel B, Bachanova V, Verneris MR, and Miller JS. A Phase II Trial of Decitabine and Vorinostat in Combination with Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia. ASH Annual Meeting Abstracts 120 4307-.2012 |
7. Bhatla T, Wang J, Morrison D, Jones C, Raetz E, Burke M, Brown P, Loh M, Hunger S, Carroll W. Evolution of the histone code in relapsed acute lymphoblastic leukemia (ALL). Pediatric Blood & Cancer June 2013;60:S40-S40. id: 348982 |
8. Bhatla T, Blum R, Wang J, Jones CL, Morrison DJ, Raetz EA, Burke MJ, Brown P, Harvey RC, Willman CL, Loh M, Hunger SP, Carroll WL. Deciphering the Epigenetic Landscape of Relapsed Pediatric Acute Lymphoblastic Leukemia. Blood 2014 124:612; published ahead of print December 5, 2014 |
9. Sasaki K, Rodriguez II, Kantarjian H, O’Brien S, Jabbour E, Borthakur G, Ravandi F, Burke M, Zweidler-McKay PA, Cortes JE.Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Blood 2014 124:4538; published ahead of print December 5, 2014 |
10. Sun W, Smith A, Sposto R, Orgel E, Wilkes JJ, Gardner R, Hur M, Pineros V, Tan Y, Rheingold SR, Burke M, Wayne AS. The UK ALLR3 (R3) Chemotherapy Regimen for Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) of Childhood: A Multi-Institutional Retrospective Study of Treatment Related Adverse Events (AEs). Blood 2014 124:3647; published ahead of print December 5, 2014 |
11. Burke MJ, Gore L, Sposto R, Bhojwani D, Chang BH, DuBois SG, Gaynon PS, Glade-Bender J, Heym KM, Huynh VT, Sulis ML, Pollard JA, Verma A, Brown P. Invasive Candida Infections in Pediatric Patients Treated on the Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. Blood 2014 124:3650; published ahead of print December 5, 2014 |
12. Salzer W, Burke MJ, Larsen EC, Chen S, Gore L, Hilden JM, Loh ML, Raetz E, Winick NJ, Carroll WL, Devidas M, Hunger SP. Incidence of allergic reactions to pegaspargase administered intramuscularly versus intravenously in children and young adults with high risk B-lymphoblastic leukemia: Results of Children's Oncology Group studies AALL0232/AALL1131. Blood. 2015;126(23):1303-1303. |
13. Rabin KR, Hitzler J, Rodriguez V, Schore R, Angiolillo A, Burke MJ, Salzer W, Maloney K, Lu X, Devidas M, Loh ML, Raetz E, Hunger SP. Treatment-related mortality in children with Down Syndrome and B-lymphoblastic leukemia: An interim report from the Children's Oncology Group trials AALL0932 and AALL1131. Blood. 2015;126(23):2502-2502. |
14. Hardy KK, Winick N, Hostetter SA, Jarel BT, Walsh KS, Annett RD, Embry L, Burke M, Salzer W, Noll RB. Promoting neurocognitive assessment participation in a large, multi-site treatment study of children with newly diagnosed acute lymphoblastic leukemia: a Children's Oncology Group study AALL1131. Proceedings of the American Academy of Pediatrics. 2014: 24579. |
15. Salzer WL, Burke M, Devidas M, Gore L, Larsen E, Zaoutis TE, Fisher B, Steinbach W, Hilden J, Loh ML, Winick N, Carroll WL, Raetz E, Sung L, Hunger S. Induction mortality and its association with invasive fungal infections (IFI) in children and young adults with high risk (HR) B-lymphoblastic leukemia (B-ALL): early results from Children’s Oncology Group study AALL1131. Pediatric Blood & Cancer. 2014; 61(S1):4015. |
16. Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. Michael J. Burke, Patrick Brown, Richard Sposto, Lia Gore, Bill H. Chang, Todd Cooper, Robyn Dennis, Steven DuBois, Rebecca Gardner, Paul Gaynon, Kenneth Heym, Van Thu Huynh, Sima Jeha, Joel Kaplan, Theodore Laetsch, Javier Oesterheld, Maria Luisa Sulis, Anupam Verma, David Ziegler, Alan Wayne. ASH 2017 abstract Blood |
17. Burke MJ, Brown P, Sposto R, Gore L, Wayne A. Pilot study of decitabine and vorinostat with chemotherapy for relapsed ALL: A report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. Blood. 2016:128(22):2781 |
18. Hampton OA, Ramos EI, Kakkar N, Junco JJ, Reuther J, Angiolillo A, Schore RJ, Burke MJ, Salzer W, Devidas M, Carroll AJ, Heerema NA, Maloney K, Winick N, Carroll WL, Raetz E, Loh ML, Hunger SP, Jain J, Doddapaneni H, Muzny DM, Wheeler DA, Fisher KE, Lopez-Terrada DH, Roy A, Parsons DW, Rabin KR. Integrated genomic analysis of Down syndrome acute lymphoblastic leukemia reveals recurrent cancer gene alterations and evidence of frequent subclonal driver events. Blood. 2016:128(22):4083. |
19. Rabin KR, Devidas M, Chen Z, Dai Y, Tasian SK, Hitzler JK, Roberts KG, Carroll AJ, Heerema NA, Borowitz MJ, Wood BL, Mullighan CG, Harvey RC, Chen IM, Willman CL, Reshmi SC, Gastier-Foster JM, Maloney KW, Larsen EC, Schore RJ, Burke MJ, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Angiolillo AL, Loh ML, Hunger SP. Outcomes of patients with Down syndrome and CRLF2-Overexpressing ALL: A report for the COG. Blood 2020 |
20. Tasian SK, Dai Y, Devidas M, Roberts KG, Harvey RC, Chen IM, Carroll AJ, Heerema NA, Reshmi SC, Gastier-Foster JM, Borowitz MJ, Wood BL, Mullighan CG, Willman CL, Maloney KW, Larsen EC, Angiolillo AL, Schore RJ, Burke MJ, Salzer WL, Winick NJ, Carroll WL, Hunger SP, Raetz EA, Rabin KR, Loh ML. Outcomes of patients with CRLF2-Overexpressing ALL without Down syndrome: A report from the COG. Blood 2020 |
21. Loh ML, DelRocco NJ, Borowitz MJ, Zweidler-McKay P, Maloney KW, Mattano LA, Larsen E, Angiolillo A, Schore RJ, Burke MJ, Salzer WL, Wood BL, Carroll AJ, Heerema NA, Reshmi S, Gastier-Foster JM, Harvey R, Chen IM, Roberts K, Mullighan C, Willman C, Winick N, Carroll WL, Hunger SP, Raetz EA, Devidas M, Kairalla JA. Enhanced risk stratification of 21,199 children, adolescents, and young adults with ALL incorporating WBC, age, MRD at day 8 and 29 as continuous variables: A COG report. Blood 2020 |
22. |
